Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Breast Cancer Res Treat

Retrieve available abstracts of 580 articles:
HTML format
Text format



Single Articles


    April 2019
  1. NOORDHOEK I, de Groot AF, Cohen D, Liefers GJ, et al
    Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05233.
    PubMed     Text format     Abstract available


  2. KHAN KA, Mazuquin B, Canaway A, Petrou S, et al
    Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05235.
    PubMed     Text format     Abstract available


  3. FLORES-DIAZ D, Arce C, Flores-Luna L, Reynoso-Noveron N, et al
    Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients.
    Breast Cancer Res Treat. 2019 Apr 17. pii: 10.1007/s10549-019-05234.
    PubMed     Text format     Abstract available


  4. MA X, Dang C, Min W, Diao Y, et al
    Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05189.
    PubMed     Text format     Abstract available


  5. LEE J, Lim B, Pearson T, Choi K, et al
    Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Apr 15. pii: 10.1007/s10549-019-05218.
    PubMed     Text format     Abstract available


  6. CHEN BT, Jin T, Patel SK, Ye N, et al
    Intrinsic brain activity changes associated with adjuvant chemotherapy in older women with breast cancer: a pilot longitudinal study.
    Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05230.
    PubMed     Text format     Abstract available


  7. CAGNEY DN, Lamba N, Montoya S, Li P, et al
    Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases.
    Breast Cancer Res Treat. 2019 Apr 13. pii: 10.1007/s10549-019-05236.
    PubMed     Text format     Abstract available


  8. DARCEY E, Lloyd R, Cadby G, Pilkington L, et al
    The association between mammographic density and breast cancer risk in Western Australian Aboriginal women.
    Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05225.
    PubMed     Text format     Abstract available


  9. BERNSTEIN-MOLHO R, Singer A, Laitman Y, Netzer I, et al
    Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
    Breast Cancer Res Treat. 2019 Apr 12. pii: 10.1007/s10549-019-05228.
    PubMed     Text format     Abstract available


  10. MUTONGA M, Speedy S, Rademaker A, Liu D, et al
    Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
    Breast Cancer Res Treat. 2019 Apr 11. pii: 10.1007/s10549-018-05088.
    PubMed     Text format     Abstract available


  11. VAN UDEN DJP, van Maaren MC, Bult P, Strobbe LJA, et al
    Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
    Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05219.
    PubMed     Text format     Abstract available


  12. NEUNER JM, Nattinger AB, Yen T, McGinley E, et al
    Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?
    Breast Cancer Res Treat. 2019 Apr 10. pii: 10.1007/s10549-019-05213.
    PubMed     Text format     Abstract available


  13. KREUTZ C, Schmidt ME, Steindorf K
    Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05217.
    PubMed     Text format     Abstract available


  14. HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
    Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women.
    Breast Cancer Res Treat. 2019 Apr 6. pii: 10.1007/s10549-019-05223.
    PubMed     Text format     Abstract available


  15. LU Y, Li J, Zhao X, Li J, et al
    Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm.
    Breast Cancer Res Treat. 2019 Apr 5. pii: 10.1007/s10549-019-05202.
    PubMed     Text format     Abstract available


  16. KUSAMA H, Shimoda M, Miyake T, Tanei T, et al
    Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues.
    Breast Cancer Res Treat. 2019 Apr 4. pii: 10.1007/s10549-019-05222.
    PubMed     Text format     Abstract available


  17. EVANS DGR, Harkness EF, Brentnall AR, van Veen EM, et al
    Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05210.
    PubMed     Text format     Abstract available


  18. KUROZUMI S, Joseph C, Raafat S, Sonbul S, et al
    Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.
    Breast Cancer Res Treat. 2019 Apr 2. pii: 10.1007/s10549-019-05216.
    PubMed     Text format     Abstract available


  19. WANG G, Qin S, Zayas J, Ingle JN, et al
    4-Hydroxytamoxifen enhances sensitivity of estrogen receptor alpha-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05194.
    PubMed     Text format     Abstract available


  20. LIN Y, Wang C, Huang X, Zhou X, et al
    Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial.
    Breast Cancer Res Treat. 2019 Apr 1. pii: 10.1007/s10549-019-05207.
    PubMed     Text format     Abstract available


    March 2019
  21. KORZETS Y, Fyles A, Shepshelovich D, Amir E, et al
    Toxicity and clinical outcomes of partial breast irradiation compared to whole breast irradiation for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Mar 30. pii: 10.1007/s10549-019-05209.
    PubMed     Text format     Abstract available


  22. DANIELL KM, Bardia A, Sun F, Roberts SA, et al
    Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Mar 27. pii: 10.1007/s10549-019-05206.
    PubMed     Text format     Abstract available


  23. AURIT SJ, Devesa SS, Soliman AS, Schairer C, et al
    Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015).
    Breast Cancer Res Treat. 2019 Mar 26. pii: 10.1007/s10549-019-05193.
    PubMed     Text format     Abstract available


  24. TORRES A, Ramdial JL, Aguirre LE, Mahtani R, et al
    Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05203.
    PubMed     Text format     Abstract available


  25. CAMARA RJA, Schwentner L, Friedl TWP, Deniz M, et al
    Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
    Breast Cancer Res Treat. 2019 Mar 21. pii: 10.1007/s10549-019-05171.
    PubMed     Text format     Abstract available


  26. CAO W, Xie Y, He Y, Li J, et al
    Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05199.
    PubMed     Text format     Abstract available


  27. VARELLA L, Eziokwu AS, Jia X, Kruse M, et al
    Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05176.
    PubMed     Text format     Abstract available


  28. HOSIO M, Urpilainen E, Marttila M, Hautakoski A, et al
    Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes.
    Breast Cancer Res Treat. 2019 Mar 20. pii: 10.1007/s10549-019-05185.
    PubMed     Text format     Abstract available


  29. DAVIS LE, Fulton C, Bubis LD, Sussman J, et al
    Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study.
    Breast Cancer Res Treat. 2019 Mar 16. pii: 10.1007/s10549-019-05196.
    PubMed     Text format     Abstract available


  30. HOLM-RASMUSSEN EV, Jensen MB, Balslev E, Kroman N, et al
    Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study.
    Breast Cancer Res Treat. 2019 Mar 14. pii: 10.1007/s10549-019-05200.
    PubMed     Text format     Abstract available


  31. YU C, Qin N, Pu Z, Song C, et al
    Integrating of genomic and transcriptomic profiles for the prognostic assessment of breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05177.
    PubMed     Text format     Abstract available


  32. MARSCHNER N, Trarbach T, Rauh J, Meyer D, et al
    Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05197.
    PubMed     Text format     Abstract available


  33. DE GROOT AF, Blok EJ, Charehbili A, Engels CC, et al
    Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05195.
    PubMed     Text format     Abstract available


  34. FASCHING PA, Gass P, Haberle L, Volz B, et al
    Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2019 Mar 13. pii: 10.1007/s10549-019-05198.
    PubMed     Text format     Abstract available


  35. TIAN J, Chen X, Fu S, Zhang R, et al
    Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05183.
    PubMed     Text format     Abstract available


  36. LYNCE F, Barac A, Geng X, Dang C, et al
    Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05191.
    PubMed     Text format     Abstract available


  37. CHRISCHILLES EA, Riley D, Letuchy E, Koehler L, et al
    Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network.
    Breast Cancer Res Treat. 2019 Mar 9. pii: 10.1007/s10549-019-05184.
    PubMed     Text format     Abstract available


  38. ZHANG B, Long EF
    Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05190.
    PubMed     Text format     Abstract available


  39. PLAVC G, Ratosa I, Zagar T, Zadnik V, et al
    Explaining variation in quality of breast cancer care and its impact: a nationwide population-based study from Slovenia.
    Breast Cancer Res Treat. 2019 Mar 7. pii: 10.1007/s10549-019-05186.
    PubMed     Text format     Abstract available


  40. KAISER K, Cameron KA, Beaumont J, Garcia SF, et al
    What does risk of future cancer mean to breast cancer patients?
    Breast Cancer Res Treat. 2019 Mar 6. pii: 10.1007/s10549-019-05182.
    PubMed     Text format     Abstract available


  41. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    ERalpha upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-kappaB in breast cancer.
    Breast Cancer Res Treat. 2019 Mar 4. pii: 10.1007/s10549-018-05108.
    PubMed     Text format     Abstract available


  42. DOEGE D, Thong MS, Koch-Gallenkamp L, Bertram H, et al
    Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany.
    Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05188.
    PubMed     Text format     Abstract available


  43. LEE J, Lim B, Pearson T, Choi K, et al
    Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Mar 2. pii: 10.1007/s10549-019-05166.
    PubMed     Text format     Abstract available


  44. VAN DOOIJEWEERT C, Deckers IAG, Baas IO, van der Wall E, et al
    Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands.
    Breast Cancer Res Treat. 2019 Mar 1. pii: 10.1007/s10549-019-05180.
    PubMed     Text format     Abstract available


    February 2019
  45. AFZALI F, Akbari P, Naderi-Manesh H, Gardaneh M, et al
    The next generation personalized models to screen hidden layers of breast cancer tumorigenicity.
    Breast Cancer Res Treat. 2019 Feb 27. pii: 10.1007/s10549-019-05159.
    PubMed     Text format     Abstract available


  46. MARKS DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, et al
    The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05169.
    PubMed     Text format     Abstract available


  47. SAGAWA N, Ohno S, Hiratsuka T, Kondo N, et al
    The utility of DHL-HisZnNa, a novel antioxidant, against anticancer agent-induced alopecia in breast cancer patients: a multicenter phase II clinical trial.
    Breast Cancer Res Treat. 2019 Feb 26. pii: 10.1007/s10549-019-05164.
    PubMed     Text format     Abstract available


  48. RICE SR, Feigenberg SJ, Hamza M, Molitoris JK, et al
    Trends in utilization of hypofractionated whole breast irradiation (HF-WBI) in triple negative breast cancer (TNBC): a national cancer database (NCDB) analysis.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05150.
    PubMed     Text format     Abstract available


  49. ACETO GM, Awadelkarim KD, Di Nicola M, Moscatello C, et al
    Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05168.
    PubMed     Text format     Abstract available


  50. TICE JA, Bissell MCS, Miglioretti DL, Gard CC, et al
    Validation of the breast cancer surveillance consortium model of breast cancer risk.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-019-05167.
    PubMed     Text format     Abstract available


  51. WUERSTLEIN R, Kates R, Gluz O, Grischke EM, et al
    Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
    Breast Cancer Res Treat. 2019 Feb 22. pii: 10.1007/s10549-018-05075.
    PubMed     Text format     Abstract available


  52. GUO L, Chen G, Zhang W, Zhou L, et al
    A high-risk luminal A dominant breast cancer subtype with increased mobility.
    Breast Cancer Res Treat. 2019 Feb 19. pii: 10.1007/s10549-019-05135.
    PubMed     Text format     Abstract available


  53. ZHAO H, Shen J, Moore SC, Ye Y, et al
    Breast cancer risk in relation to plasma metabolites among Hispanic and African American women.
    Breast Cancer Res Treat. 2019 Feb 15. pii: 10.1007/s10549-019-05165.
    PubMed     Text format     Abstract available


  54. KOTSOPOULOS J, Lubinski J, Lynch HT, Tung N, et al
    Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05162.
    PubMed     Text format     Abstract available


  55. STAVRAKA C, Pouptsis A, Okonta L, DeSouza K, et al
    Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05144.
    PubMed     Text format     Abstract available


  56. GREGOROWITSCH ML, Ghedri A, Young-Afat DA, Bijlsma R, et al
    The effect of chemotherapy on subjective cognitive function in younger early-stage breast cancer survivors treated with chemotherapy compared to older patients.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05149.
    PubMed     Text format     Abstract available


  57. YANG SX, Polley EC
    Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
    Breast Cancer Res Treat. 2019 Feb 12. pii: 10.1007/s10549-019-05142.
    PubMed     Text format     Abstract available


  58. LAN Y, Zhao E, Luo S, Xiao Y, et al
    Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
    Breast Cancer Res Treat. 2019 Feb 9. pii: 10.1007/s10549-019-05153.
    PubMed     Text format     Abstract available


  59. O'MEARA T, Safonov A, Casadevall D, Qing T, et al
    Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05156.
    PubMed     Text format     Abstract available


  60. BICK U, Engel C, Krug B, Heindel W, et al
    High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-019-05152.
    PubMed     Text format     Abstract available


  61. LIU Y, Pandey PR, Sharma S, Xing F, et al
    ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness.
    Breast Cancer Res Treat. 2019 Feb 6. pii: 10.1007/s10549-018-05126.
    PubMed     Text format     Abstract available


  62. HUSSAIN Y, Drill E, Dang CT, Liu JE, et al
    Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05139.
    PubMed     Text format     Abstract available


  63. DICKINSON SL, Golzarri-Arroyo L, Brown AW, McComb B, et al
    Change in study randomization allocation needs to be included in statistical analysis: comment on 'Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEA
    Breast Cancer Res Treat. 2019 Feb 5. pii: 10.1007/s10549-019-05155.
    PubMed     Text format    


  64. SUN M, Wu D, Zhou K, Li H, et al
    An eight-lncRNA signature predicts survival of breast cancer patients: a comprehensive study based on weighted gene co-expression network analysis and competing endogenous RNA network.
    Breast Cancer Res Treat. 2019 Feb 4. pii: 10.1007/s10549-019-05147.
    PubMed     Text format     Abstract available


  65. LIGABUE MB, Campanini I, Veroni P, Cepelli A, et al
    Efficacy of self-administered complex decongestive therapy on breast cancer-related lymphedema: a single-blind randomized controlled trial.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05136.
    PubMed     Text format     Abstract available


  66. LIU ZH, Wang K, Lin DY, Xu J, et al
    Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Breast Cancer Res Treat. 2019 Feb 2. pii: 10.1007/s10549-019-05148.
    PubMed     Text format     Abstract available


  67. ALTUNDAG K
    HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment.
    Breast Cancer Res Treat. 2019 Feb 1. pii: 10.1007/s10549-019-05151.
    PubMed     Text format    


    January 2019
  68. FATEHI S, Maasoumi R, Atashsokhan G, Hamidzadeh A, et al
    The effects of psychosexual counseling on sexual quality of life and function in Iranian breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res Treat. 2019 Jan 30. pii: 10.1007/s10549-019-05140.
    PubMed     Text format     Abstract available


  69. SZIJGYARTO Z, Flach KD, Opdam M, Palmieri C, et al
    Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
    Breast Cancer Res Treat. 2019 Jan 24. pii: 10.1007/s10549-018-05110.
    PubMed     Text format     Abstract available


  70. CAMP NJ, Madsen MJ, Herranz J, Rodriguez-Lescure A, et al
    Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 23. pii: 10.1007/s10549-018-05097.
    PubMed     Text format     Abstract available


  71. SUH KJ, Ryu HS, Lee KH, Kim H, et al
    Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-019-05128.
    PubMed     Text format     Abstract available


  72. EL-ANSARI R, Craze ML, Alfarsi L, Soria D, et al
    The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
    Breast Cancer Res Treat. 2019 Jan 22. pii: 10.1007/s10549-018-05111.
    PubMed     Text format     Abstract available


  73. WEISS A, Grossmith S, Cutts D, Mikami SA, et al
    Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk.
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05116.
    PubMed     Text format     Abstract available


  74. COOPEY SB, Kartal K, Li C, Yala A, et al
    Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
    Breast Cancer Res Treat. 2019 Jan 21. pii: 10.1007/s10549-018-05117.
    PubMed     Text format     Abstract available


  75. ROBERTSON S, Ronnlund C, de Boniface J, Hartman J, et al
    Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05119.
    PubMed     Text format     Abstract available


  76. PETRELLI F, Ghidini A, Pedersini R, Cabiddu M, et al
    Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-019-05133.
    PubMed     Text format     Abstract available


  77. XU X, Chlebowski RT, Shi J, Barac A, et al
    Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Breast Cancer Res Treat. 2019 Jan 18. pii: 10.1007/s10549-018-05086.
    PubMed     Text format     Abstract available


  78. BATTISTI NML, Kingston B, King J, Denton A, et al
    Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Breast Cancer Res Treat. 2019 Jan 17. pii: 10.1007/s10549-019-05134.
    PubMed     Text format     Abstract available


  79. FRIEDLAENDER A, Vuilleumier A, Viassolo V, Ayme A, et al
    BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 11. pii: 10.1007/s10549-018-05127.
    PubMed     Text format     Abstract available


  80. RUGO HS, Finn RS, Dieras V, Ettl J, et al
    Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05125.
    PubMed     Text format     Abstract available


  81. HASHEMI SM, Balouchi A, Al-Mawali A, Rafiemanesh H, et al
    Health-related quality of life of breast cancer patients in the Eastern Mediterranean region: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05131.
    PubMed     Text format     Abstract available


  82. GADALLA R, Hassan H, Ibrahim SA, Abdullah MS, et al
    Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05129.
    PubMed     Text format     Abstract available


  83. NITZ U, Gluz O, Christgen M, Kates RE, et al
    Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-018-05105.
    PubMed     Text format     Abstract available


  84. STOVGAARD ES, Dyhl-Polk A, Roslind A, Balslev E, et al
    PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.
    Breast Cancer Res Treat. 2019 Jan 10. pii: 10.1007/s10549-019-05130.
    PubMed     Text format     Abstract available


  85. LUBINSKI J, Huzarski T, Gronwald J, Cybulski C, et al
    Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers.
    Breast Cancer Res Treat. 2019 Jan 5. pii: 10.1007/s10549-018-05076.
    PubMed     Text format     Abstract available


  86. ALHUDIRI IM, Nolan CC, Ellis IO, Elzagheid A, et al
    Expression of Lamin A/C in early-stage breast cancer and its prognostic value.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05092.
    PubMed     Text format     Abstract available


  87. VANE MLG, Willemsen MA, van Roozendaal LM, van Kuijk SMJ, et al
    Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05074.
    PubMed     Text format     Abstract available


  88. BOWDEN AR, Tischkowitz M
    Clinical implications of germline mutations in breast cancer genes: RECQL.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05096.
    PubMed     Text format     Abstract available


  89. CHENG ES, Yu XQ
    Re: The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer. Breast Cancer Res Treat. Sep 2018;171(2):477-488.
    Breast Cancer Res Treat. 2019 Jan 4. pii: 10.1007/s10549-018-05101.
    PubMed     Text format    


  90. AUSTIN AM, Kapadia NS, Brooks GA, Onega TL, et al
    Comparison of treatment of early-stage breast cancer among Nurses' Health Study participants and other Medicare beneficiaries.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05098.
    PubMed     Text format     Abstract available


  91. YAMAMOTO T, Kanaya N, Somlo G, Chen S, et al
    Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05104.
    PubMed     Text format     Abstract available


  92. YANG Z, Ouyang T, Li J, Wang T, et al
    Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05124.
    PubMed     Text format     Abstract available


  93. LUSTIG DB, Warburton R, Dingee CK, Kuusk U, et al
    Is microductectomy still necessary to diagnose breast cancer: a 10-year study on the effectiveness of duct excision and galactography.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05109.
    PubMed     Text format     Abstract available


  94. OCANA A, Gil-Martin M, Antolin S, Atienza M, et al
    Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
    Breast Cancer Res Treat. 2019 Jan 3. pii: 10.1007/s10549-018-05100.
    PubMed     Text format     Abstract available


  95. KENSLER KH, Eliassen AH, Rosner BA, Hankinson SE, et al
    Pre-diagnostic sex hormone levels and survival among breast cancer patients.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05121.
    PubMed     Text format     Abstract available


  96. PATEL DA, Xi J, Luo J, Hassan B, et al
    Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05106.
    PubMed     Text format     Abstract available


  97. O'BRIEN P, Matheson K, Jeyakumar A, Anderson K, et al
    The clinical utility of baseline cardiac assessments prior to adjuvant anthracycline chemotherapy in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05114.
    PubMed     Text format     Abstract available


  98. KIM SJ, Zhang CXW, Demsky R, Armel S, et al
    Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05118.
    PubMed     Text format     Abstract available


  99. CARUANA E, Foucher Y, Tessier P, Frenel JS, et al
    Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05107.
    PubMed     Text format     Abstract available


  100. WUNDERLE M, Pretscher J, Brucker SY, Volz B, et al
    Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05115.
    PubMed     Text format     Abstract available


  101. GOGATE A, Rotter JS, Trogdon JG, Meng K, et al
    An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-05099.
    PubMed     Text format     Abstract available


  102. HU J, Wang X, Guo S, Chen F, et al
    Peer support interventions for breast cancer patients: a systematic review.
    Breast Cancer Res Treat. 2019 Jan 2. pii: 10.1007/s10549-018-5033.
    PubMed     Text format     Abstract available


    December 2018
  103. LYES MA, Payne S, Ferrell P, Pizzo SV, et al
    Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence.
    Breast Cancer Res Treat. 2018 Dec 29. pii: 10.1007/s10549-018-05103.
    PubMed     Text format     Abstract available


  104. THEBERGE I, Vandal N, Guertin MH, Perron L, et al
    The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women's characteristics: is it the same?
    Breast Cancer Res Treat. 2018 Dec 18. pii: 10.1007/s10549-018-05095.
    PubMed     Text format     Abstract available


  105. MALMGREN J, Hurlbert M, Atwood M, Kaplan HG, et al
    Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05090.
    PubMed     Text format     Abstract available


  106. BUTTON B, Croessmann S, Chu D, Rosen DM, et al
    The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05087.
    PubMed     Text format     Abstract available


  107. KIM JH, Yoon KH, Hur H, Park S, et al
    Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.
    Breast Cancer Res Treat. 2018 Dec 17. pii: 10.1007/s10549-018-05091.
    PubMed     Text format     Abstract available


  108. JOSEPH C, Arshad M, Kurozomi S, Althobiti M, et al
    Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
    Breast Cancer Res Treat. 2018 Dec 15. pii: 10.1007/s10549-018-05085.
    PubMed     Text format     Abstract available


  109. JOHANSSON ALV, Weibull CE, Fredriksson I, Lambe M, et al
    Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05083.
    PubMed     Text format     Abstract available


  110. DURAN-LOZANO L, Montalban G, Bonache S, Moles-Fernandez A, et al
    Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T.
    Breast Cancer Res Treat. 2018 Dec 14. pii: 10.1007/s10549-018-05094.
    PubMed     Text format     Abstract available


  111. RAGHAVENDRA A, Wecsler J, Ji L, Sheth P, et al
    Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    Breast Cancer Res Treat. 2018 Dec 12. pii: 10.1007/s10549-018-05084.
    PubMed     Text format     Abstract available


  112. WANG XM, Zhang Z, Pan LH, Cao XC, et al
    KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Breast Cancer Res Treat. 2018 Dec 8. pii: 10.1007/s10549-018-05069.
    PubMed     Text format     Abstract available


  113. NANNI O, Amadori D, De Censi A, Rocca A, et al
    Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
    Breast Cancer Res Treat. 2018 Dec 7. pii: 10.1007/s10549-018-05070.
    PubMed     Text format     Abstract available


  114. PARANJPE R, John G, Trivedi M, Abughosh S, et al
    Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
    Breast Cancer Res Treat. 2018 Dec 6. pii: 10.1007/s10549-018-05073.
    PubMed     Text format     Abstract available


  115. DONENBERG T, George S, Ali J, Bravo G, et al
    A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Breast Cancer Res Treat. 2018 Dec 4. pii: 10.1007/s10549-018-5045.
    PubMed     Text format     Abstract available


  116. COUGHLIN SS, Paxton RJ, Moore N, Stewart JL, et al
    Survivorship issues in older breast cancer survivors.
    Breast Cancer Res Treat. 2018 Dec 1. pii: 10.1007/s10549-018-05078.
    PubMed     Text format     Abstract available


  117. MCCLATCHY DM 3RD, Zuurbier RA, Wells WA, Paulsen KD, et al
    Micro-computed tomography enables rapid surgical margin assessment during breast conserving surgery (BCS): correlation of whole BCS micro-CT readings to final histopathology.
    Breast Cancer Res Treat. 2018;172:587-595.
    PubMed     Text format     Abstract available


  118. MCMULLEN ER, Gonzalez ME, Skala SL, Tran M, et al
    CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast.
    Breast Cancer Res Treat. 2018;172:577-586.
    PubMed     Text format     Abstract available


    November 2018
  119. LIDBRINK E, Chmielowska E, Otremba B, Bouhlel A, et al
    A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
    Breast Cancer Res Treat. 2018 Nov 30. pii: 10.1007/s10549-018-5058.
    PubMed     Text format     Abstract available


  120. WALSH EM, Shalaby A, O'Loughlin M, Keane N, et al
    Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Breast Cancer Res Treat. 2018 Nov 28. pii: 10.1007/s10549-018-5066.
    PubMed     Text format     Abstract available


  121. HOLLERN DP, Contreras CM, Dance-Barnes S, Silva GO, et al
    A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5061.
    PubMed     Text format     Abstract available


  122. SHTAM T, Naryzhny S, Samsonov R, Karasik D, et al
    Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling.
    Breast Cancer Res Treat. 2018 Nov 27. pii: 10.1007/s10549-018-5043.
    PubMed     Text format     Abstract available


  123. ABOUEGYLAH M, Braunstein LZ, Alm El-Din MA, Niemierko A, et al
    Evaluation of radiation-induced cardiac toxicity in breast cancer patients treated with Trastuzumab-based chemotherapy.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5053.
    PubMed     Text format     Abstract available


  124. GIBBS LD, Chaudhary P, Mansheim K, Hare RJ, et al
    ANXA2 expression in African American triple-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5030.
    PubMed     Text format     Abstract available


  125. IGNATOV T, Claus M, Nass N, Haybaeck J, et al
    G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.
    Breast Cancer Res Treat. 2018 Nov 26. pii: 10.1007/s10549-018-5064.
    PubMed     Text format     Abstract available


  126. CHASAMPALIOTI M, Green AR, Ellis IO, Rakha EA, et al
    Connexin 43 is an independent predictor of patient outcome in breast cancer patients.
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5063.
    PubMed     Text format     Abstract available


  127. HENRY DA, Lee MC, Almanza D, Ahmed KA, et al
    Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    Breast Cancer Res Treat. 2018 Nov 24. pii: 10.1007/s10549-018-5057.
    PubMed     Text format     Abstract available


  128. CRAZE ML, El-Ansari R, Aleskandarany MA, Cheng KW, et al
    Glutamate dehydrogenase (GLUD1) expression in breast cancer.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5060.
    PubMed     Text format     Abstract available


  129. LOO LWM, Gao C, Shvetsov YB, Okoro DR, et al
    MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5065.
    PubMed     Text format     Abstract available


  130. WANG J, Xu B, Wang W, Zhai X, et al
    Correction to: Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Nov 23. pii: 10.1007/s10549-018-5047.
    PubMed     Text format     Abstract available


  131. ROZNER RN, Freites-Martinez A, Shapiro J, Geer EB, et al
    Safety of 5alpha-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.
    Breast Cancer Res Treat. 2018 Nov 22. pii: 10.1007/s10549-018-4996.
    PubMed     Text format     Abstract available


  132. DIBABA DT, Ogunsina K, Braithwaite D, Akinyemiju T, et al
    Metabolic syndrome and risk of breast cancer mortality by menopause, obesity, and subtype.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5056.
    PubMed     Text format     Abstract available


  133. HASKINS CB, McDowell BD, Carnahan RM, Fiedorowicz JG, et al
    Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5050.
    PubMed     Text format     Abstract available


  134. CAPARICA R, Bruzzone M, Poggio F, Ceppi M, et al
    Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5055.
    PubMed     Text format     Abstract available


  135. ZOOROB RJ, Salemi JL, Mejia de Grubb MC, Modak S, et al
    A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5059.
    PubMed     Text format     Abstract available


  136. LEE KWC, Lord S, Finn RS, Lim E, et al
    The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2018 Nov 21. pii: 10.1007/s10549-018-5054.
    PubMed     Text format     Abstract available


  137. CAO J, Eshak ES, Liu K, Muraki I, et al
    Sleep duration and risk of breast cancer: The JACC Study.
    Breast Cancer Res Treat. 2018 Nov 20. pii: 10.1007/s10549-018-4995.
    PubMed     Text format     Abstract available


  138. JONGEN L, Floris G, Boeckx B, Smeets D, et al
    Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations.
    Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5049.
    PubMed     Text format     Abstract available


  139. LIU J, Liu L, Yague E, Yang Q, et al
    GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
    Breast Cancer Res Treat. 2018 Nov 19. pii: 10.1007/s10549-018-5052.
    PubMed     Text format     Abstract available


  140. CORSO G, Pravettoni G, Galimberti V, Veronesi P, et al
    Clinical implication of E-cadherin deficiency in lobular breast cancer.
    Breast Cancer Res Treat. 2018 Nov 17. pii: 10.1007/s10549-018-5051.
    PubMed     Text format    


  141. XU R, Tang P, Li C
    Association between pre-operative magnetic resonance imaging (MRI) and surgical outcomes in breast cancer: not yet determined.
    Breast Cancer Res Treat. 2018 Nov 16. pii: 10.1007/s10549-018-5010.
    PubMed     Text format    


  142. BLEICHER RJ, Chang C, Wang CE, Goldstein LJ, et al
    Treatment delays from transfers of care and their impact on breast cancer quality measures.
    Breast Cancer Res Treat. 2018 Nov 15. pii: 10.1007/s10549-018-5046.
    PubMed     Text format     Abstract available


  143. MORTEN BC, Chiu S, Oldmeadow C, Lubinski J, et al
    The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Nov 14. pii: 10.1007/s10549-018-5039.
    PubMed     Text format     Abstract available


  144. DESANTIS CE, Ma J, Jemal A
    Trends in stage at diagnosis for young breast cancer patients in the United States.
    Breast Cancer Res Treat. 2018 Nov 13. pii: 10.1007/s10549-018-5042.
    PubMed     Text format     Abstract available


  145. KIM YH, Hwang JH, Bae JH, Choi JY, et al
    Predictive value of lymphoscintigraphy in patients with breast cancer-related lymphedema undergoing complex decongestive therapy.
    Breast Cancer Res Treat. 2018 Nov 12. pii: 10.1007/s10549-018-5041.
    PubMed     Text format     Abstract available


  146. DROGEMOLLER BI, Wright GEB, Shih J, Monzon JG, et al
    CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
    Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5027.
    PubMed     Text format     Abstract available


  147. BUSCARIOLLO DL, Cronin AM, Borstelmann NA, Punglia RS, et al
    Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women.
    Breast Cancer Res Treat. 2018 Nov 8. pii: 10.1007/s10549-018-5006.
    PubMed     Text format     Abstract available


  148. GUDINA AT, Copeland G, Soliman AS, Hirko KA, et al
    Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.
    Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5037.
    PubMed     Text format     Abstract available


  149. SKULI SJ, Sheng JY, Bantug ET, Zafman N, et al
    Survivorship care visits in a high-risk population of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Nov 7. pii: 10.1007/s10549-018-5028.
    PubMed     Text format     Abstract available


  150. XUE C, Wei W, Sun P, Zheng W, et al
    Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-4997.
    PubMed     Text format     Abstract available


  151. HOPPE EJ, Hussain LR, Grannan KJ, Dunki-Jacobs EM, et al
    Racial disparities in breast cancer persist despite early detection: analysis of treatment of stage 1 breast cancer and effect of insurance status on disparities.
    Breast Cancer Res Treat. 2018 Nov 3. pii: 10.1007/s10549-018-5036.
    PubMed     Text format     Abstract available


  152. LI T, Yang J, Lv Y, Yin F, et al
    Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer.
    Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5029.
    PubMed     Text format     Abstract available


  153. PARK S, Moon BI, Oh SJ, Lee HB, et al
    Clinical subtypes and prognosis in breast cancer according to parity: a nationwide study in Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2018 Nov 2. pii: 10.1007/s10549-018-5032.
    PubMed     Text format     Abstract available


  154. HENG YJ, Wang J, Ahearn TU, Brown SB, et al
    Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.
    Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5034.
    PubMed     Text format     Abstract available


  155. SZOSTAKOWSKA M, Trebinska-Stryjewska A, Grzybowska EA, Fabisiewicz A, et al
    Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals.
    Breast Cancer Res Treat. 2018 Nov 1. pii: 10.1007/s10549-018-5023.
    PubMed     Text format     Abstract available


  156. SUNG JS, Corben AD, Brooks JD, Edelweiss M, et al
    Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
    Breast Cancer Res Treat. 2018;172:487-496.
    PubMed     Text format     Abstract available


  157. NARAYAN AK, Elkin EB, Lehman CD, Morris EA, et al
    Quantifying performance thresholds for recommending screening mammography: a revealed preference analysis of USPSTF guidelines.
    Breast Cancer Res Treat. 2018;172:463-468.
    PubMed     Text format     Abstract available


  158. SANCHEZ-SPITMAN AB, Dezentje VO, Swen JJ, Moes DJAR, et al
    Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy.
    Breast Cancer Res Treat. 2018;172:401-411.
    PubMed     Text format     Abstract available


  159. WU NC, Wong W, Ho KE, Chu VC, et al
    Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Breast Cancer Res Treat. 2018;172:327-338.
    PubMed     Text format     Abstract available


  160. REGMI S, Fung TS, Lim S, Luo KQ, et al
    Fluidic shear stress increases the anti-cancer effects of ROS-generating drugs in circulating tumor cells.
    Breast Cancer Res Treat. 2018;172:297-312.
    PubMed     Text format     Abstract available


  161. TUDINI E, Moghadasi S, Parsons MT, van der Kolk L, et al
    Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val).
    Breast Cancer Res Treat. 2018;172:497-503.
    PubMed     Text format     Abstract available


  162. YEAP PM, Evans A, Purdie CA, Jordan LB, et al
    A comparison of the imaging features of pleomorphic and classical invasive lobular carcinoma.
    Breast Cancer Res Treat. 2018;172:381-389.
    PubMed     Text format     Abstract available


  163. PAREKH A, Fu W, Hu C, Shen CJ, et al
    Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database.
    Breast Cancer Res Treat. 2018;172:201-208.
    PubMed     Text format     Abstract available


  164. ALSHAKER H, Srivats S, Monteil D, Wang Q, et al
    Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.
    Breast Cancer Res Treat. 2018;172:33-43.
    PubMed     Text format     Abstract available


  165. BARNES-KEDAR I, Bernstein-Molho R, Ginzach N, Hartmajer S, et al
    The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
    Breast Cancer Res Treat. 2018;172:151-157.
    PubMed     Text format     Abstract available


    October 2018
  166. YOON TI, Kwak BS, Yi OV, Kim S, et al
    Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women.
    Breast Cancer Res Treat. 2018 Oct 30. pii: 10.1007/s10549-018-5031.
    PubMed     Text format     Abstract available


  167. VALLET S, Fan F, Malvestiti S, Pecherstorfer M, et al
    Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
    Breast Cancer Res Treat. 2018 Oct 29. pii: 10.1007/s10549-018-5022.
    PubMed     Text format     Abstract available


  168. RODRIGUES-FERREIRA S, Nehlig A, Monchecourt C, Nasr S, et al
    Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5026.
    PubMed     Text format     Abstract available


  169. CAO S, Zhou J, Zhu Z, Wei F, et al
    Adult weight change and the risk of pre- and postmenopausal breast cancer in the Chinese Wuxi Exposure and Breast Cancer Study.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-5016.
    PubMed     Text format     Abstract available


  170. WALTER KR, Ford ME, Gregoski MJ, Kramer RM, et al
    Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.
    Breast Cancer Res Treat. 2018 Oct 27. pii: 10.1007/s10549-018-4992.
    PubMed     Text format     Abstract available


  171. MASKARINEC G, Shvetsov YB, Conroy SM, Haiman CA, et al
    Type 2 diabetes as a predictor of survival among breast cancer patients: the multiethnic cohort.
    Breast Cancer Res Treat. 2018 Oct 26. pii: 10.1007/s10549-018-5025.
    PubMed     Text format     Abstract available


  172. LIU GY, Li JW, Zuo WJ, Ivanova D, et al
    Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5024.
    PubMed     Text format     Abstract available


  173. OHARA AM, Naoi Y, Shimazu K, Kagara N, et al
    PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5020.
    PubMed     Text format     Abstract available


  174. JONCZYK MM, Jean J, Graham R, Chatterjee A, et al
    Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis.
    Breast Cancer Res Treat. 2018 Oct 25. pii: 10.1007/s10549-018-5018.
    PubMed     Text format     Abstract available


  175. CABEL L, Carton M, Cheaib B, Pierga JY, et al
    Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
    Breast Cancer Res Treat. 2018 Oct 24. pii: 10.1007/s10549-018-5017.
    PubMed     Text format     Abstract available


  176. VAN DEN BERG MMGA, Kok DE, Posthuma L, Kamps L, et al
    Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 23. pii: 10.1007/s10549-018-5014.
    PubMed     Text format     Abstract available


  177. JEREVALL PL, Brock J, Palazzo J, Wieczorek T, et al
    Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5013.
    PubMed     Text format     Abstract available


  178. RYU JM, Choi HJ, Kim I, Nam SJ, et al
    Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
    Breast Cancer Res Treat. 2018 Oct 22. pii: 10.1007/s10549-018-5015.
    PubMed     Text format     Abstract available


  179. BLANCO C, Markowitz JC, Hellerstein DJ, Nezu AM, et al
    A randomized trial of interpersonal psychotherapy, problem solving therapy, and supportive therapy for major depressive disorder in women with breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4994.
    PubMed     Text format     Abstract available


  180. WU T, Sultan LR, Tian J, Cary TW, et al
    Machine learning for diagnostic ultrasound of triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-4984.
    PubMed     Text format     Abstract available


  181. ALTUNDAG K
    Extranodular extension in sentinel lymph node-positive breast cancer might predict further initiation of completion axillary lymph node dissection.
    Breast Cancer Res Treat. 2018 Oct 20. pii: 10.1007/s10549-018-5019.
    PubMed     Text format    


  182. HE X, Ji J, Dong R, Liu H, et al
    Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
    Breast Cancer Res Treat. 2018 Oct 19. pii: 10.1007/s10549-018-5005.
    PubMed     Text format     Abstract available


  183. SOPIK V, Sun P, Narod SA
    Predictors of time to death after distant recurrence in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5002.
    PubMed     Text format     Abstract available


  184. LEONARDIS JM, Diefenbach BJ, Lyons DA, Olinger TA, et al
    The influence of reconstruction choice and inclusion of radiation therapy on functional shoulder biomechanics in women undergoing mastectomy for breast cancer.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-5003.
    PubMed     Text format     Abstract available


  185. CAIN EH, Saha A, Harowicz MR, Marks JR, et al
    Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
    Breast Cancer Res Treat. 2018 Oct 16. pii: 10.1007/s10549-018-4990.
    PubMed     Text format     Abstract available


  186. FASCHING PA, Hartkopf AD, Gass P, Haberle L, et al
    Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5008.
    PubMed     Text format     Abstract available


  187. ALTUNDAG K
    Better pathological tumor characteristics might occur in recurrent metastatic breast cancer patients after 10-year metastatic free interval.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-5011.
    PubMed     Text format    


  188. HWANG HW, Jung H, Hyeon J, Park YH, et al
    A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4981.
    PubMed     Text format     Abstract available


  189. TERADA M
    Challenge for identifying the origin of occult breast cancer for optimizing local therapy.
    Breast Cancer Res Treat. 2018 Oct 15. pii: 10.1007/s10549-018-4931.
    PubMed     Text format    


  190. INNO A, Barni S, Ghidini A, Zaniboni A, et al
    One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-5001.
    PubMed     Text format     Abstract available


  191. ASTASHCHANKA A, Shroka TM, Jacobsen BM
    Mucin 2 (MUC2) modulates the aggressiveness of breast cancer.
    Breast Cancer Res Treat. 2018 Oct 13. pii: 10.1007/s10549-018-4989.
    PubMed     Text format     Abstract available


  192. HENNIGS A, Kopke M, Feisst M, Riedel F, et al
    Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Breast Cancer Res Treat. 2018 Oct 12. pii: 10.1007/s10549-018-5009.
    PubMed     Text format     Abstract available


  193. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Correction to: Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2018 Oct 11. pii: 10.1007/s10549-018-4975.
    PubMed     Text format     Abstract available


  194. GUESTINI F, Ono K, Miyashita M, Ishida T, et al
    Impact of Topoisomerase IIalpha, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4985.
    PubMed     Text format     Abstract available


  195. ALFARSI LH, Elansari R, Toss MS, Diez-Rodriguez M, et al
    Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4978.
    PubMed     Text format     Abstract available


  196. KUSSAIBI H, Alkharsah KR, Altamimi D, Alsayyah A, et al
    Alternative splicing is an important mechanism behind KAI1 loss of function in breast cancer patients from Saudi Arabia.
    Breast Cancer Res Treat. 2018 Oct 10. pii: 10.1007/s10549-018-4999.
    PubMed     Text format     Abstract available


  197. KRAMER CJH, Vangangelt KMH, van Pelt GW, Dekker TJA, et al
    The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review.
    Breast Cancer Res Treat. 2018 Oct 9. pii: 10.1007/s10549-018-4987.
    PubMed     Text format     Abstract available


  198. REN JX, Gong Y, Ling H, Hu X, et al
    Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics.
    Breast Cancer Res Treat. 2018 Oct 6. pii: 10.1007/s10549-018-4956.
    PubMed     Text format     Abstract available


  199. JAUCH SF, Riethdorf S, Sprick MR, Schutz F, et al
    Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Oct 1. pii: 10.1007/s10549-018-4972.
    PubMed     Text format     Abstract available


  200. JANSEN LE, Teft WA, Rose RV, Lizotte DJ, et al
    CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.
    Breast Cancer Res Treat. 2018;171:701-708.
    PubMed     Text format     Abstract available


  201. LURASCHI R, Lazzari R, Galimberti V, Rondi E, et al
    Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED).
    Breast Cancer Res Treat. 2018;171:693-699.
    PubMed     Text format     Abstract available


  202. COELHO BA, Paiva SPC, da Silva Filho AL
    Extremely brief mindfulness interventions for women undergoing breast biopsies: a randomized controlled trial.
    Breast Cancer Res Treat. 2018;171:685-692.
    PubMed     Text format     Abstract available


  203. EULER-CHELPIN MV, Lillholm M, Napolitano G, Vejborg I, et al
    Screening mammography: benefit of double reading by breast density.
    Breast Cancer Res Treat. 2018;171:767-776.
    PubMed     Text format     Abstract available


    September 2018
  204. GUCALP A, Traina TA, Eisner JR, Parker JS, et al
    Male breast cancer: a disease distinct from female breast cancer.
    Breast Cancer Res Treat. 2018 Sep 28. pii: 10.1007/s10549-018-4921.
    PubMed     Text format     Abstract available


  205. SIMONE BA, Ko K, Simone NL
    Re: Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2018 Sep 27. pii: 10.1007/s10549-018-4940.
    PubMed     Text format    


  206. ZUNIGA KE, Parma DL, Munoz E, Spaniol M, et al
    Dietary intervention among breast cancer survivors increased adherence to a Mediterranean-style, anti-inflammatory dietary pattern: the Rx for Better Breast Health Randomized Controlled Trial.
    Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4982.
    PubMed     Text format     Abstract available


  207. RESNICOW K, Patel MR, Mcleod MC, Katz SJ, et al
    Physician attitudes about cost consciousness for breast cancer treatment: differences by cancer sub-specialty.
    Breast Cancer Res Treat. 2018 Sep 26. pii: 10.1007/s10549-018-4976.
    PubMed     Text format     Abstract available


  208. SMETANAY K, Junio P, Feisst M, Seitz J, et al
    COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2018 Sep 25. pii: 10.1007/s10549-018-4983.
    PubMed     Text format     Abstract available


  209. XU R, Zhu J
    Association between red and processed meat with breast cancer: Comment on "Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies" by Guo et al.
    Breast Cancer Res Treat. 2018 Sep 24. pii: 10.1007/s10549-018-4977.
    PubMed     Text format    


  210. BHARGAVA A, Saha S
    T-Type voltage gated calcium channels: a target in breast cancer?
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4970.
    PubMed     Text format     Abstract available


  211. SHEN Y, Fujii T, Ueno NT, Tripathy D, et al
    Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4969.
    PubMed     Text format     Abstract available


  212. IWATA H, Masuda N, Yamamoto Y, Fujisawa T, et al
    Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4964.
    PubMed     Text format     Abstract available


  213. CHANG E, Mougalian SS, Adelson KB, Young MR, et al
    Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database.
    Breast Cancer Res Treat. 2018 Sep 21. pii: 10.1007/s10549-018-4968.
    PubMed     Text format     Abstract available


  214. ACEVEDO F, Armengol VD, Deng Z, Tang R, et al
    Pathologic findings in reduction mammoplasty specimens: a surrogate for the population prevalence of breast cancer and high-risk lesions.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4962.
    PubMed     Text format     Abstract available


  215. LEE SK, Kim SW, Yu JH, Lee JE, et al
    Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer?
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4947.
    PubMed     Text format     Abstract available


  216. HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
    Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4944.
    PubMed     Text format     Abstract available


  217. NIRAULA S, Gyawali B
    Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2018 Sep 20. pii: 10.1007/s10549-018-4967.
    PubMed     Text format     Abstract available


  218. TONG WL, Callahan BM, Tu YN, Zaman S, et al
    Immune receptor recombinations from breast cancer exome files, independently and in combination with specific HLA alleles, correlate with better survival rates.
    Breast Cancer Res Treat. 2018 Sep 18. pii: 10.1007/s10549-018-4961.
    PubMed     Text format     Abstract available


  219. FALATO C, Taylor SK, Szulkin R, Nordblom A, et al
    Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4936.
    PubMed     Text format     Abstract available


  220. LIU Z, Sahli Z, Wang Y, Wolff AC, et al
    Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study.
    Breast Cancer Res Treat. 2018 Sep 17. pii: 10.1007/s10549-018-4950.
    PubMed     Text format     Abstract available


  221. SPRING L, Niemierko A, Haddad S, Yuen M, et al
    Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
    Breast Cancer Res Treat. 2018 Sep 15. pii: 10.1007/s10549-018-4959.
    PubMed     Text format     Abstract available


  222. RYU JM, Choi HJ, Kim I, Lee SK, et al
    Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4948.
    PubMed     Text format     Abstract available


  223. KHALED H, Gamal H, Lotayef M, Knauer M, et al
    The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view.
    Breast Cancer Res Treat. 2018 Sep 14. pii: 10.1007/s10549-018-4945.
    PubMed     Text format     Abstract available


  224. OLIVA-MORENO J, Pena-Longobardo LM
    Labour productivity loss caused by premature deaths associated with breast cancer: results from Spain over a 10-year period.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4963.
    PubMed     Text format     Abstract available


  225. JEON SH, Shin KH, Kim JH, Kim K, et al
    Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
    Breast Cancer Res Treat. 2018 Sep 12. pii: 10.1007/s10549-018-4966.
    PubMed     Text format     Abstract available


  226. PEREZ-PENA J, Gyorffy B, Amir E, Pandiella A, et al
    Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
    Breast Cancer Res Treat. 2018 Sep 11. pii: 10.1007/s10549-018-4965.
    PubMed     Text format     Abstract available


  227. TAKADA M, Sugimoto M, Masuda N, Iwata H, et al
    Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
    Breast Cancer Res Treat. 2018 Sep 7. pii: 10.1007/s10549-018-4958.
    PubMed     Text format     Abstract available


  228. FENTIMAN IS
    Surgical options for male breast cancer.
    Breast Cancer Res Treat. 2018 Sep 5. pii: 10.1007/s10549-018-4952.
    PubMed     Text format     Abstract available


  229. ALTUNDAG K
    Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients.
    Breast Cancer Res Treat. 2018 Sep 3. pii: 10.1007/s10549-018-4949.
    PubMed     Text format    


  230. OZAWA PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, et al
    Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells.
    Breast Cancer Res Treat. 2018 Sep 1. pii: 10.1007/s10549-018-4925.
    PubMed     Text format     Abstract available


    August 2018
  231. NAROD SA, Giannakeas V, Sopik V
    Time to death in breast cancer patients as an indicator of treatment response.
    Breast Cancer Res Treat. 2018 Aug 30. pii: 10.1007/s10549-018-4935.
    PubMed     Text format     Abstract available


  232. SHEN S, Unger JM, Crew KD, Till C, et al
    Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4946.
    PubMed     Text format     Abstract available


  233. MOORE AH, Trentham-Dietz A, Burns M, Gangnon RE, et al
    Obesity and mortality after locoregional breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4932.
    PubMed     Text format     Abstract available


  234. ZHANG Z, Li C, Fan H, Xiang Q, et al
    Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4942.
    PubMed     Text format     Abstract available


  235. DE SOUZA TIMOTEO AR, Goncalves AEMM, Sales LAP, Albuquerque BM, et al
    A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4938.
    PubMed     Text format     Abstract available


  236. THOMAS R, Rowell R, Crichton S, Cain H, et al
    Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure.
    Breast Cancer Res Treat. 2018 Aug 29. pii: 10.1007/s10549-018-4943.
    PubMed     Text format     Abstract available


  237. FRONTERA ED, Khansa RM, Schalk DL, Leakan LE, et al
    IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2018 Aug 28. pii: 10.1007/s10549-018-4941.
    PubMed     Text format     Abstract available


  238. GOTO-YAMAGUCHI L, Yamamoto-Ibusuki M, Yamamoto Y, Fujiki Y, et al
    Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4933.
    PubMed     Text format     Abstract available


  239. YANG J, Lv Q
    Theoretical possibility of primary breast cancer originates from ectopic breast tissue in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Aug 27. pii: 10.1007/s10549-018-4926.
    PubMed     Text format    


  240. ALTUNDAG K
    Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases.
    Breast Cancer Res Treat. 2018 Aug 24. pii: 10.1007/s10549-018-4934.
    PubMed     Text format    


  241. BALLINGER TJ, Reddy A, Althouse SK, Nelson EM, et al
    Impact of primary breast cancer therapy on energetic capacity and body composition.
    Breast Cancer Res Treat. 2018 Aug 22. pii: 10.1007/s10549-018-4924.
    PubMed     Text format     Abstract available


  242. WANG B, Yuan F
    The association between estrogen receptor alpha gene rs746432 polymorphism and the risk of breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4929.
    PubMed     Text format    


  243. BAE SY, Nam SJ, Jung Y, Lee SB, et al
    Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4928.
    PubMed     Text format     Abstract available


  244. BEMANIAN V, Noone JC, Sauer T, Touma J, et al
    Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4927.
    PubMed     Text format     Abstract available


  245. SONG EJ, Lee CW, Jung SY, Kim BN, et al
    Prognostic impact of skeletal muscle volume derived from cross-sectional computed tomography images in breast cancer.
    Breast Cancer Res Treat. 2018 Aug 21. pii: 10.1007/s10549-018-4915.
    PubMed     Text format     Abstract available


  246. RAMOS J, Das J, Felty Q, Yoo C, et al
    NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Breast Cancer Res Treat. 2018 Aug 20. pii: 10.1007/s10549-018-4905.
    PubMed     Text format     Abstract available


  247. CLAESSENS AKM, Bos MEMM, Lopez-Yurda M, Bouma JM, et al
    Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG).
    Breast Cancer Res Treat. 2018 Aug 18. pii: 10.1007/s10549-018-4906.
    PubMed     Text format     Abstract available


  248. KENN M, Cacsire Castillo-Tong D, Singer CF, Cibena M, et al
    Co-expressed genes enhance precision of receptor status identification in breast cancer patients.
    Breast Cancer Res Treat. 2018 Aug 16. pii: 10.1007/s10549-018-4920.
    PubMed     Text format     Abstract available


  249. KRABY MR, Valla M, Opdahl S, Haugen OA, et al
    The prognostic value of androgen receptors in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Aug 14. pii: 10.1007/s10549-018-4904.
    PubMed     Text format     Abstract available


  250. BUHL ASK, Christensen TD, Christensen IJ, Nelausen KM, et al
    Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4918.
    PubMed     Text format     Abstract available


  251. WANG SY, Long JB, Killelea BK, Evans SB, et al
    Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4919.
    PubMed     Text format     Abstract available


  252. BARBOSA C ROCHA F, Falcone AB, Buzaid AC, Pimenta JM, et al
    Neoadjuvant therapy for breast cancer treatment: an expert panel recommendation from the Brazilian Society of Breast Surgeons 2018.
    Breast Cancer Res Treat. 2018 Aug 11. pii: 10.1007/s10549-018-4912.
    PubMed     Text format     Abstract available


  253. GREEN AK, Aviki EM, Matsoukas K, Patil S, et al
    Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4909.
    PubMed     Text format     Abstract available


  254. BORRIE AE, Rose RV, Choi YH, Perera FE, et al
    Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 9. pii: 10.1007/s10549-018-4910.
    PubMed     Text format     Abstract available


  255. LEE SB, Ko SS, Park CH, Nam SJ, et al
    Chronologically changing patterns in the survival of korean patients with breast cancer and related clinical factors: a nationwide registry-based study.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4892.
    PubMed     Text format     Abstract available


  256. CHEN BT, Jin T, Patel SK, Ye N, et al
    Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4911.
    PubMed     Text format     Abstract available


  257. BAE SY, Kim SJ, Lee J, Lee ES, et al
    Clinical subtypes and prognosis of pregnancy-associated breast cancer: results from the Korean Breast Cancer Society Registry database.
    Breast Cancer Res Treat. 2018 Aug 7. pii: 10.1007/s10549-018-4908.
    PubMed     Text format     Abstract available


  258. MURPHY J, Pfeiffer RM, Lynn BCD, Caballero AI, et al
    Pro-inflammatory cytokines and growth factors in human milk: an exploratory analysis of racial differences to inform breast cancer etiology.
    Breast Cancer Res Treat. 2018 Aug 6. pii: 10.1007/s10549-018-4907.
    PubMed     Text format     Abstract available


  259. ZDRAVKOVIC D, Nikolic D, Zdravkovic M
    Heterogeneity of tumor cells and metastases in breast cancer patients: cause or consequence?
    Breast Cancer Res Treat. 2018 Aug 4. pii: 10.1007/s10549-018-4913.
    PubMed     Text format    


  260. LIN CH, Tang CH
    Rebuttal comments on "Glucocorticoids in breast cancer treatment: Real benefit or selection bias?"
    Breast Cancer Res Treat. 2018 Aug 2. pii: 10.1007/s10549-018-4872.
    PubMed     Text format    


    July 2018
  261. SANFT T, Usiskin I, Harrigan M, Cartmel B, et al
    Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4895.
    PubMed     Text format     Abstract available


  262. SUN F, Hall A, Tighe MP, Brunelle CL, et al
    Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2018 Jul 30. pii: 10.1007/s10549-018-4902.
    PubMed     Text format     Abstract available


  263. FELIZ-MOSQUEA YR, Christensen AA, Wilson AS, Westwood B, et al
    Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4884.
    PubMed     Text format     Abstract available


  264. KUROZUMI S, Joseph C, Sonbul S, Aleskandarany MA, et al
    Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer.
    Breast Cancer Res Treat. 2018 Jul 28. pii: 10.1007/s10549-018-4891.
    PubMed     Text format     Abstract available


  265. MESSINA C, Cattrini C, Buzzatti G, Cerbone L, et al
    CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4901.
    PubMed     Text format     Abstract available


  266. LIN JH, Tu SH, Chen LC, Huang CC, et al
    Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 27. pii: 10.1007/s10549-018-4897.
    PubMed     Text format     Abstract available


  267. GUNER G, Dizdar O
    Glucocorticoids in breast cancer treatment: real benefit or selection bias?
    Breast Cancer Res Treat. 2018 Jul 26. pii: 10.1007/s10549-018-4871.
    PubMed     Text format    


  268. FARSHID G, Walters D
    Molecular subtypes of screen-detected breast cancer.
    Breast Cancer Res Treat. 2018 Jul 25. pii: 10.1007/s10549-018-4899.
    PubMed     Text format     Abstract available


  269. MADDEN JM, Murphy L, Zgaga L, Bennett K, et al
    De novo vitamin D supplement use post-diagnosis is associated with breast cancer survival.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4896.
    PubMed     Text format     Abstract available


  270. SHARIF-ASKARI B, Amrein L, Aloyz R, Panasci L, et al
    PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
    Breast Cancer Res Treat. 2018 Jul 23. pii: 10.1007/s10549-018-4888.
    PubMed     Text format     Abstract available


  271. WULANINGSIH W, Garmo H, Ahlgren J, Holmberg L, et al
    Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
    Breast Cancer Res Treat. 2018 Jul 21. pii: 10.1007/s10549-018-4890.
    PubMed     Text format     Abstract available


  272. TERADA M, Adachi Y, Sawaki M, Hattori M, et al
    Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 Jul 20. pii: 10.1007/s10549-018-4898.
    PubMed     Text format     Abstract available


  273. SOLDERA SV, Ennis M, Lohmann AE, Goodwin PJ, et al
    Sexual health in long-term breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jul 19. pii: 10.1007/s10549-018-4894.
    PubMed     Text format     Abstract available


  274. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for breast cancer staging.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4893.
    PubMed     Text format     Abstract available


  275. MCCALL NS, Simone BA, Mehta M, Zhan T, et al
    Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer.
    Breast Cancer Res Treat. 2018 Jul 18. pii: 10.1007/s10549-018-4880.
    PubMed     Text format     Abstract available


  276. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jul 16. pii: 10.1007/s10549-018-4883.
    PubMed     Text format     Abstract available


  277. VAN NULAND M, Vreman RA, Ten Ham RMT, de Vries Schultink AHM, et al
    Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4886.
    PubMed     Text format     Abstract available


  278. O'BRIEN KM, Mooney T, Fitzpatrick P, Sharp L, et al
    Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
    Breast Cancer Res Treat. 2018 Jul 13. pii: 10.1007/s10549-018-4877.
    PubMed     Text format     Abstract available


  279. REDITI M, Messina C
    Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4885.
    PubMed     Text format    


  280. BANYS-PALUCHOWSKI M, Witzel I, Riethdorf S, Pantel K, et al
    The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jul 12. pii: 10.1007/s10549-018-4882.
    PubMed     Text format     Abstract available


  281. SAHA A, Harowicz MR, Cain EH, Hall AH, et al
    Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
    Breast Cancer Res Treat. 2018 Jul 10. pii: 10.1007/s10549-018-4879.
    PubMed     Text format     Abstract available


  282. NIKOLIC D, Granic M, Ivanovic N, Zdravkovic D, et al
    Breast cancer and its impact in male transsexuals.
    Breast Cancer Res Treat. 2018 Jul 5. pii: 10.1007/s10549-018-4875.
    PubMed     Text format     Abstract available


  283. ANGARITA FA, Elmi M, Zhang Y, Look Hong NJ, et al
    Patient-reported factors influencing the treatment decision-making process of older women with non-metastatic breast cancer: a systematic review of qualitative evidence.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4865.
    PubMed     Text format     Abstract available


  284. ROBINSON A, Souied O, Bota AB, Levasseur N, et al
    Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4868.
    PubMed     Text format     Abstract available


  285. WANG J, Xu B, Wang W, Zhai X, et al
    Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Breast Cancer Res Treat. 2018 Jul 4. pii: 10.1007/s10549-018-4867.
    PubMed     Text format     Abstract available


  286. KABIL N, Bayraktar R, Kahraman N, Mokhlis HA, et al
    Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4847.
    PubMed     Text format     Abstract available


  287. BERTHE A, Zaffino M, Muller C, Foulquier F, et al
    Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4874.
    PubMed     Text format     Abstract available


  288. SAGARA Y, Takada M, Ohi Y, Ohtani S, et al
    Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.
    Breast Cancer Res Treat. 2018 Jul 3. pii: 10.1007/s10549-018-4873.
    PubMed     Text format     Abstract available


    June 2018
  289. BRENNAN M, Gass P, Haberle L, Wang D, et al
    The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer.
    Breast Cancer Res Treat. 2018 Jun 27. pii: 10.1007/s10549-018-4829.
    PubMed     Text format     Abstract available


  290. STOUT NK, Cronin AM, Uno H, Ozanne EM, et al
    Estrogen-receptor status and risk of contralateral breast cancer following DCIS.
    Breast Cancer Res Treat. 2018 Jun 26. pii: 10.1007/s10549-018-4860.
    PubMed     Text format     Abstract available


  291. LEE DY, Park YH, Lee JE, Choi D, et al
    Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4863.
    PubMed     Text format     Abstract available


  292. VAN SWEARINGEN AED, Siegel MB, Deal AM, Sambade MJ, et al
    LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.
    Breast Cancer Res Treat. 2018 Jun 25. pii: 10.1007/s10549-018-4852.
    PubMed     Text format     Abstract available


  293. YAP YS, Munusamy P, Lim C, Chan CHT, et al
    Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4851.
    PubMed     Text format     Abstract available


  294. KIM JY, Lim JE, Jung HH, Cho SY, et al
    Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4858.
    PubMed     Text format     Abstract available


  295. BAUER ECA, Schochter F, Widschwendter P, DeGregorio A, et al
    Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
    Breast Cancer Res Treat. 2018 Jun 21. pii: 10.1007/s10549-018-4856.
    PubMed     Text format     Abstract available


  296. MARTIN M, de la Torre-Montero JC, Lopez-Tarruella S, Pinilla K, et al
    Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling.
    Breast Cancer Res Treat. 2018 Jun 19. pii: 10.1007/s10549-018-4855.
    PubMed     Text format     Abstract available


  297. PEREIRA PTVT, Reis AD, Diniz RR, Lima FA, et al
    Dietary supplements and fatigue in patients with breast cancer: a systematic review.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4857.
    PubMed     Text format     Abstract available


  298. JERZAK KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, et al
    Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4844.
    PubMed     Text format     Abstract available


  299. KOGAWA T, Fujii T, Fouad TM, Liu DD, et al
    Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Jun 18. pii: 10.1007/s10549-018-4853.
    PubMed     Text format     Abstract available


  300. LI X, Zhang Y, Meisel J, Jiang R, et al
    Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database.
    Breast Cancer Res Treat. 2018 Jun 15. pii: 10.1007/s10549-018-4832.
    PubMed     Text format     Abstract available


  301. LANGBALLE R, Frederiksen K, Jensen MB, Andersson M, et al
    Mortality after contralateral breast cancer in Denmark.
    Breast Cancer Res Treat. 2018 Jun 11. pii: 10.1007/s10549-018-4846.
    PubMed     Text format     Abstract available


  302. MANDUJANO-TINOCO EA, Garcia-Venzor A, Melendez-Zajgla J, Maldonado V, et al
    New emerging roles of microRNAs in breast cancer.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4850.
    PubMed     Text format     Abstract available


  303. SMITH BL, Gadd MA, Lanahan CR, Rai U, et al
    Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system.
    Breast Cancer Res Treat. 2018 Jun 9. pii: 10.1007/s10549-018-4845.
    PubMed     Text format     Abstract available


  304. LOTSCH J, Sipila R, Tasmuth T, Kringel D, et al
    Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy.
    Breast Cancer Res Treat. 2018 Jun 6. pii: 10.1007/s10549-018-4841.
    PubMed     Text format     Abstract available


  305. KONG AL, Nattinger AB, McGinley E, Pezzin LE, et al
    The relationship between patient and tumor characteristics, patterns of breast cancer care, and 5-year survival among elderly women with incident breast cancer.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4837.
    PubMed     Text format     Abstract available


  306. ROUMELIOTIS M, Long K, Phan T, Graham D, et al
    Including internal mammary lymph nodes in radiation therapy for synchronous bilateral breast cancer: an international survey of treatment technique and clinical priorities.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4848.
    PubMed     Text format     Abstract available


  307. CHA YJ, Ahn SG, Bae SJ, Yoon CI, et al
    Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4842.
    PubMed     Text format     Abstract available


  308. PICADO O, Khazeni K, Allen C, Yakoub D, et al
    Extent of regional lymph node surgery and impact on outcomes in patients with early-stage breast cancer and limited axillary disease undergoing mastectomy.
    Breast Cancer Res Treat. 2018 Jun 5. pii: 10.1007/s10549-018-4840.
    PubMed     Text format     Abstract available


  309. LEOPOLD C, Wagner AK, Zhang F, Lu CY, et al
    Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4819.
    PubMed     Text format     Abstract available


  310. REDDY JP, Atkinson RL, Larson R, Burks JK, et al
    Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4835.
    PubMed     Text format     Abstract available


  311. ARIAS-PULIDO H, Cimino-Mathews A, Chaher N, Qualls C, et al
    The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4834.
    PubMed     Text format     Abstract available


  312. EVANS A, Sim YT, Pourreyron C, Thompson A, et al
    Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival.
    Breast Cancer Res Treat. 2018 Jun 1. pii: 10.1007/s10549-018-4836.
    PubMed     Text format     Abstract available


    May 2018
  313. JAIN S, Shah AN, Santa-Maria CA, Siziopikou K, et al
    Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4792.
    PubMed     Text format     Abstract available


  314. ANDERSSON Y, Bergkvist L, Frisell J, de Boniface J, et al
    Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Breast Cancer Res Treat. 2018 May 30. pii: 10.1007/s10549-018-4820.
    PubMed     Text format     Abstract available


  315. JACOB L, Scholten PC, Kostev K, Kalder M, et al
    Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4831.
    PubMed     Text format     Abstract available


  316. WANG Z, Katsaros D, Biglia N, Shen Y, et al
    High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4839.
    PubMed     Text format     Abstract available


  317. LIU J, Yang Y, Wang H, Wang B, et al
    Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Breast Cancer Res Treat. 2018 May 29. pii: 10.1007/s10549-018-4833.
    PubMed     Text format     Abstract available


  318. ELMI M, Sequeira S, Azin A, Elnahas A, et al
    Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    Breast Cancer Res Treat. 2018 May 28. pii: 10.1007/s10549-018-4830.
    PubMed     Text format     Abstract available


  319. LI D, McCall LM, Hahn OM, Hudis CA, et al
    Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.
    Breast Cancer Res Treat. 2018 May 22. pii: 10.1007/s10549-018-4828.
    PubMed     Text format     Abstract available


  320. MASUMOTO N, Kadoya T, Sasada S, Emi A, et al
    Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer.
    Breast Cancer Res Treat. 2018 May 19. pii: 10.1007/s10549-018-4791.
    PubMed     Text format     Abstract available


  321. KOTSOPOULOS J, Gronwald J, Lynch HT, Eisen A, et al
    Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4822.
    PubMed     Text format     Abstract available


  322. O'LOUGHLIN M, Andreu X, Bianchi S, Chemielik E, et al
    Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
    Breast Cancer Res Treat. 2018 May 17. pii: 10.1007/s10549-018-4825.
    PubMed     Text format     Abstract available


  323. WILLIAMSON TJ, Love SM, Clague DeHart JN, Jorge-Miller A, et al
    Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE).
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4823.
    PubMed     Text format     Abstract available


  324. HOSTE G, Punie K, Wildiers H, Beuselinck B, et al
    Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 16. pii: 10.1007/s10549-018-4827.
    PubMed     Text format     Abstract available


  325. BLOK EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, et al
    Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2018 May 15. pii: 10.1007/s10549-018-4785.
    PubMed     Text format     Abstract available


  326. LIN CH, Chuang PY, You SL, Chiang CJ, et al
    Effect of glucocorticoid use on survival in patients with stage I-III breast cancer.
    Breast Cancer Res Treat. 2018 May 14. pii: 10.1007/s10549-018-4787.
    PubMed     Text format     Abstract available


  327. LU CY, Zhang F, Wagner AK, Nekhlyudov L, et al
    Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.
    Breast Cancer Res Treat. 2018 May 12. pii: 10.1007/s10549-018-4821.
    PubMed     Text format     Abstract available


  328. ONO H, Sowa Y, Horinaka M, Iizumi Y, et al
    The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
    Breast Cancer Res Treat. 2018 May 11. pii: 10.1007/s10549-018-4815.
    PubMed     Text format     Abstract available


  329. LOWRY KP, Braunstein LZ, Economopoulos KP, Salama L, et al
    Predictors of surveillance mammography outcomes in women with a personal history of breast cancer.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4808.
    PubMed     Text format     Abstract available


  330. WANG S, Beeghly-Fadiel A, Cai Q, Cai H, et al
    Gene expression in triple-negative breast cancer in relation to survival.
    Breast Cancer Res Treat. 2018 May 10. pii: 10.1007/s10549-018-4816.
    PubMed     Text format     Abstract available


  331. HUANG Z, Shi Y, Bao P, Cai H, et al
    Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4805.
    PubMed     Text format     Abstract available


  332. BARDIA A, Gucalp A, DaCosta N, Gabrail N, et al
    Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 9. pii: 10.1007/s10549-018-4813.
    PubMed     Text format     Abstract available


  333. CHOI JY, Cho EY, Choi YJ, Lee JH, et al
    Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4809.
    PubMed     Text format     Abstract available


  334. CUI P, Zhao Y, Chu X, He N, et al
    SNP rs2071095 in LincRNA H19 is associated with breast cancer risk.
    Breast Cancer Res Treat. 2018 May 8. pii: 10.1007/s10549-018-4814.
    PubMed     Text format     Abstract available


  335. DANIELS B, Kiely BE, Lord SJ, Houssami N, et al
    Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4804.
    PubMed     Text format     Abstract available


  336. TELLI ML, Stover DG, Loi S, Aparicio S, et al
    Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 May 7. pii: 10.1007/s10549-018-4807.
    PubMed     Text format     Abstract available


  337. TSUNASHIMA R, Naoi Y, Shimazu K, Kagara N, et al
    Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4812.
    PubMed     Text format     Abstract available


  338. ABRAHAM J, Coleman R, Elias A, Holmes FA, et al
    Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).
    Breast Cancer Res Treat. 2018 May 4. pii: 10.1007/s10549-018-4783.
    PubMed     Text format     Abstract available


  339. WUNDERLE M, Gass P, Haberle L, Flesch VM, et al
    BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
    Breast Cancer Res Treat. 2018 May 3. pii: 10.1007/s10549-018-4797.
    PubMed     Text format     Abstract available


  340. KOMMALAPATI A, Tella SH, Goyal G, Ganti AK, et al
    A prognostic scoring model for survival after locoregional therapy in de novo stage IV breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4802.
    PubMed     Text format     Abstract available


  341. ERIN N, Ogan N, Yerlikaya A
    Correction to: Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 May 2. pii: 10.1007/s10549-018-4781.
    PubMed     Text format     Abstract available


    April 2018
  342. KIM S, Ko Y, Lee HJ, Lim JE, et al
    Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies.
    Breast Cancer Res Treat. 2018 Apr 30. pii: 10.1007/s10549-018-4782.
    PubMed     Text format     Abstract available


  343. SHIMA H, Kida K, Adachi S, Yamada A, et al
    Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4793.
    PubMed     Text format     Abstract available


  344. VOCI A, Lee D, Ho E, Crane-Okada R, et al
    Impact of port site scar on perception of patients with breast cancer: patient-reported outcomes.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4790.
    PubMed     Text format     Abstract available


  345. BACHAND J, Soulos PR, Herrin J, Pollack CE, et al
    Physician peer group characteristics and timeliness of breast cancer surgery.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4789.
    PubMed     Text format     Abstract available


  346. HAQUE W, Verma V, Hatch S, Suzanne Klimberg V, et al
    Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4801.
    PubMed     Text format     Abstract available


  347. SOPIK V, Narod SA
    The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4796.
    PubMed     Text format     Abstract available


  348. HACKETT J, Thorneloe R, Side L, Wolf M, et al
    Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.
    Breast Cancer Res Treat. 2018 Apr 24. pii: 10.1007/s10549-018-4775.
    PubMed     Text format     Abstract available


  349. O'SHAUGHNESSY J, DeMichele A, Ma CX, Richards P, et al
    A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
    Breast Cancer Res Treat. 2018 Apr 19. pii: 10.1007/s10549-018-4770.
    PubMed     Text format     Abstract available


  350. KROENKE CH, Hershman DL, Gomez SL, Adams SR, et al
    Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Breast Cancer Res Treat. 2018 Apr 18. pii: 10.1007/s10549-018-4774.
    PubMed     Text format     Abstract available


  351. SOARES FALCETTA F, de Araujo Vianna Trasel H, de Almeida FK, Rangel Ribeiro Falcetta M, et al
    Effects of physical exercise after treatment of early breast cancer: systematic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4786.
    PubMed     Text format     Abstract available


  352. VERMA S, O'Shaughnessy J, Burris HA, Campone M, et al
    Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
    Breast Cancer Res Treat. 2018 Apr 13. pii: 10.1007/s10549-018-4769.
    PubMed     Text format     Abstract available


  353. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
    An estrogen-related lifestyle score is associated with risk of postmenopausal breast cancer in the PLCO cohort.
    Breast Cancer Res Treat. 2018 Apr 12. pii: 10.1007/s10549-018-4784.
    PubMed     Text format     Abstract available


  354. ARTHUR R, Wang Y, Ye K, Glass AG, et al
    Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.
    Breast Cancer Res Treat. 2018 Apr 11. pii: 10.1007/s10549-018-4780.
    PubMed     Text format     Abstract available


  355. LARSEN SB, Torstensson M, Kenborg L, Christensen J, et al
    Pre-diagnostic changes in body mass index and mortality among breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 10. pii: 10.1007/s10549-018-4771.
    PubMed     Text format     Abstract available


  356. KUROZUMI S, Joseph C, Sonbul S, Gorringe KL, et al
    Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.
    Breast Cancer Res Treat. 2018 Apr 9. pii: 10.1007/s10549-018-4777.
    PubMed     Text format     Abstract available


  357. PETROSSIAN K, Nguyen D, Lo C, Kanaya N, et al
    Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4779.
    PubMed     Text format     Abstract available


  358. CHECK DK, Chawla N, Kwan ML, Pinheiro L, et al
    Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient-provider interactions.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4776.
    PubMed     Text format     Abstract available


  359. RAU KM, Ou-Yang F, Chao TC, Kuo YL, et al
    Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
    Breast Cancer Res Treat. 2018 Apr 5. pii: 10.1007/s10549-018-4778.
    PubMed     Text format     Abstract available


  360. GHILLI M, Mariniello MD, Scatena C, Dosa L, et al
    Male secretory breast cancer: case in a 6-year-old boy with a peculiar gene duplication and review of the literature.
    Breast Cancer Res Treat. 2018 Apr 3. pii: 10.1007/s10549-018-4772.
    PubMed     Text format     Abstract available


  361. SCHWARTZ MD, Peshkin BN, Isaacs C, Willey S, et al
    Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    Breast Cancer Res Treat. 2018 Apr 2. pii: 10.1007/s10549-018-4773.
    PubMed     Text format     Abstract available


    March 2018
  362. MUNZONE E, Gray KP, Fumagalli C, Guerini-Rocco E, et al
    Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Breast Cancer Res Treat. 2018 Mar 27. pii: 10.1007/s10549-018-4767.
    PubMed     Text format     Abstract available


  363. CHOWDHURY M, Euhus D, Arun B, Umbricht C, et al
    Validation of a personalized risk prediction model for contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4763.
    PubMed     Text format     Abstract available


  364. BHAT RR, Yadav P, Sahay D, Bhargava DK, et al
    GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer.
    Breast Cancer Res Treat. 2018 Mar 24. pii: 10.1007/s10549-018-4751.
    PubMed     Text format     Abstract available


  365. CAI H, Guo W, Zhang S, Li N, et al
    A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4758.
    PubMed     Text format     Abstract available


  366. PHILLIPS M, Cataneo RN, Cruz-Ramos JA, Huston J, et al
    Prediction of breast cancer risk with volatile biomarkers in breath.
    Breast Cancer Res Treat. 2018 Mar 23. pii: 10.1007/s10549-018-4764.
    PubMed     Text format     Abstract available


  367. RISI E, Grilli A, Migliaccio I, Biagioni C, et al
    A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4766.
    PubMed     Text format     Abstract available


  368. AGERSBORG S, Mixon C, Nguyen T, Aithal S, et al
    Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4755.
    PubMed     Text format     Abstract available


  369. HILL DA, Friend S, Lomo L, Wiggins C, et al
    Breast cancer survival, survival disparities, and guideline-based treatment.
    Breast Cancer Res Treat. 2018 Mar 22. pii: 10.1007/s10549-018-4761.
    PubMed     Text format     Abstract available


  370. DUFFY MJ, Synnott NC, Crown J
    Mutant p53 in breast cancer: potential as a therapeutic target and biomarker.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4753.
    PubMed     Text format     Abstract available


  371. CHATTERJEE S, Chaubal R, Maitra A, Gardi N, et al
    Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4749.
    PubMed     Text format     Abstract available


  372. BOYD J
    A parallel model for breast cancer metastasis.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4759.
    PubMed     Text format    


  373. SCHAYEK H, Korach H, Laitman Y, Bernstein-Molho R, et al
    Mutational analysis of candidate genes in Israeli male breast cancer cases.
    Breast Cancer Res Treat. 2018 Mar 21. pii: 10.1007/s10549-018-4765.
    PubMed     Text format     Abstract available


  374. LI M, Zhou Y, Xia T, Zhou X, et al
    Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4757.
    PubMed     Text format     Abstract available


  375. ALTUNDAG K
    Receptor conversion in breast cancer patients with liver metastases after hepatectomy might affect survival.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4762.
    PubMed     Text format    


  376. ERIN N, Ogan N, Yerlikaya A
    Secretomes reveal several novel proteins as well as TGF-beta1 as the top upstream regulator of metastatic process in breast cancer.
    Breast Cancer Res Treat. 2018 Mar 20. pii: 10.1007/s10549-018-4752.
    PubMed     Text format     Abstract available


  377. THONE K, Rudolph A, Obi N, Chang-Claude J, et al
    Prognostic impact of surgery for early-stage invasive breast cancer on breast cancer-specific survival, overall survival, and recurrence risk: a population-based analysis.
    Breast Cancer Res Treat. 2018 Mar 19. pii: 10.1007/s10549-018-4754.
    PubMed     Text format     Abstract available


  378. KYKER-SNOWMAN K, Erlanger Avigdor B, Nasim M, Cimino-Mathews A, et al
    A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4742.
    PubMed     Text format     Abstract available


  379. ANGARITA FA, Acuna SA, Cordeiro E, Elnahas A, et al
    Thirty-day postoperative morbidity and mortality in elderly women with breast cancer: an analysis of the NSQIP database.
    Breast Cancer Res Treat. 2018 Mar 15. pii: 10.1007/s10549-018-4747.
    PubMed     Text format     Abstract available


  380. BOUYA S, Koochakzai M, Rafiemanesh H, Balouchi A, et al
    Health-related quality of life of Iranian breast cancer patients: a meta-analysis and systematic review.
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4750.
    PubMed     Text format     Abstract available


  381. NAROD SA
    Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?
    Breast Cancer Res Treat. 2018 Mar 14. pii: 10.1007/s10549-018-4739.
    PubMed     Text format    


  382. WILSON LE, Pollack CE, Greiner MA, Dinan MA, et al
    Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
    Breast Cancer Res Treat. 2018 Mar 13. pii: 10.1007/s10549-018-4746.
    PubMed     Text format     Abstract available


  383. TURNER TH, Alzubi MA, Sohal SS, Olex AL, et al
    Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Mar 12. pii: 10.1007/s10549-018-4748.
    PubMed     Text format     Abstract available


  384. ROY P, Leizorovicz A, Villet R, Mercier C, et al
    Systematic versus sentinel-lymph-node-driven axillary-lymph-node dissection in clinically node-negative patients with operable breast cancer. Results of the GF-GS01 randomized trial.
    Breast Cancer Res Treat. 2018 Mar 10. pii: 10.1007/s10549-018-4733.
    PubMed     Text format     Abstract available


  385. LI Y, Opyrchal M, Yao S, Peng X, et al
    The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
    Breast Cancer Res Treat. 2018 Mar 9. pii: 10.1007/s10549-018-4745.
    PubMed     Text format     Abstract available


  386. BAO T, Iris Zhi W, Vertosick EA, Li QS, et al
    Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4743.
    PubMed     Text format     Abstract available


  387. BLANCHETTE PS, Desautels DN, Pond GR, Bartlett JMS, et al
    Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4734.
    PubMed     Text format     Abstract available


  388. PARK SJ, Lee MH, Kong SY, Song MK, et al
    Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4740.
    PubMed     Text format     Abstract available


  389. VELASQUEZ GARCIA HA, Sobolev BG, Gotay CC, Wilson CM, et al
    Mammographic non-dense area and breast cancer risk in postmenopausal women: a causal inference approach in a case-control study.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4737.
    PubMed     Text format     Abstract available


  390. ONEGA T, Zhu W, Weiss JE, Goodrich M, et al
    Preoperative breast MRI and mortality in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4732.
    PubMed     Text format     Abstract available


  391. ADAMS BD, Arem H, Hubal MJ, Cartmel B, et al
    Exercise and weight loss interventions and miRNA expression in women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4738.
    PubMed     Text format     Abstract available


  392. CHOWDHURY M, Euhus D, O'Donnell M, Onega T, et al
    Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4736.
    PubMed     Text format     Abstract available


  393. RICE MS, Tamimi RM, Bertrand KA, Scott CG, et al
    Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.
    Breast Cancer Res Treat. 2018 Mar 3. pii: 10.1007/s10549-018-4735.
    PubMed     Text format     Abstract available


    February 2018
  394. GERNAAT SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, et al
    The risk of cardiovascular disease following breast cancer by Framingham risk score.
    Breast Cancer Res Treat. 2018 Feb 28. pii: 10.1007/s10549-018-4723.
    PubMed     Text format     Abstract available


  395. KUSHNER CJ, Hwang WT, Wang S, Solin LJ, et al
    Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer.
    Breast Cancer Res Treat. 2018 Feb 27. pii: 10.1007/s10549-018-4729.
    PubMed     Text format     Abstract available


  396. CHEN R, Ye Y, Yang C, Peng Y, et al
    Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4730.
    PubMed     Text format     Abstract available


  397. BRONTE G, Ravaioli S, Bravaccini S
    What to look for in cell-free DNA from breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4728.
    PubMed     Text format    


  398. CHENG J, Burwinkel B
    Cell-free DNA in breast cancer: a long way to go.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4731.
    PubMed     Text format    


  399. EBER-SCHULZ P, Tariku W, Reibold C, Addissie A, et al
    Survival of breast cancer patients in rural Ethiopia.
    Breast Cancer Res Treat. 2018 Feb 26. pii: 10.1007/s10549-018-4724.
    PubMed     Text format     Abstract available


  400. DE VRIES YC, Boesveldt S, Kelfkens CS, Posthuma EE, et al
    Taste and smell perception and quality of life during and after systemic therapy for breast cancer.
    Breast Cancer Res Treat. 2018 Feb 23. pii: 10.1007/s10549-018-4720.
    PubMed     Text format     Abstract available


  401. CLIFTON K, Gutierrez-Barrera A, Ma J, Bassett R Jr., et al
    Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4727.
    PubMed     Text format     Abstract available


  402. BAUMANN FT, Reike A, Reimer V, Schumann M, et al
    Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review.
    Breast Cancer Res Treat. 2018 Feb 22. pii: 10.1007/s10549-018-4725.
    PubMed     Text format     Abstract available


  403. CHA YJ, Kim ES, Koo JS
    Tumor-associated macrophages and crown-like structures in adipose tissue in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4722.
    PubMed     Text format     Abstract available


  404. JOHNSON J, Bessette DC, Saunus JM, Smart CE, et al
    Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient.
    Breast Cancer Res Treat. 2018 Feb 21. pii: 10.1007/s10549-018-4719.
    PubMed     Text format     Abstract available


  405. RUIZ A, Sebagh M, Wicherts DA, Castro-Benitez C, et al
    Long-term survival and cure model following liver resection for breast cancer metastases.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4714.
    PubMed     Text format     Abstract available


  406. RUDOLPH M, Sizemore ST, Lu Y, Teng KY, et al
    A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Feb 20. pii: 10.1007/s10549-018-4718.
    PubMed     Text format     Abstract available


  407. WEISS A, Menen RS, Lin HY, Shen Y, et al
    Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4715.
    PubMed     Text format     Abstract available


  408. TOT T
    Metastasis of breast cancer prior to invasion.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4721.
    PubMed     Text format    


  409. JACOBS DHM, Speijer G, Petoukhova AL, Roeloffzen EMA, et al
    Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients.
    Breast Cancer Res Treat. 2018 Feb 19. pii: 10.1007/s10549-018-4712.
    PubMed     Text format     Abstract available


  410. TOLKACH Y, Gevensleben H, Bundschuh R, Koyun A, et al
    Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4717.
    PubMed     Text format     Abstract available


  411. WAGNER LI, Zhao F, Goss PE, Chapman JW, et al
    Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (
    Breast Cancer Res Treat. 2018 Feb 17. pii: 10.1007/s10549-018-4713.
    PubMed     Text format     Abstract available


  412. SCHAIRER C, Freedman DM, Gadalla SM, Pfeiffer RM, et al
    Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.
    Breast Cancer Res Treat. 2018 Feb 15. pii: 10.1007/s10549-018-4680.
    PubMed     Text format     Abstract available


  413. SHOEMAKER ML, White MC, Wu M, Weir HK, et al
    Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4699.
    PubMed     Text format     Abstract available


  414. GIANNAKEAS V, Sopik V, Narod SA
    A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis.
    Breast Cancer Res Treat. 2018 Feb 14. pii: 10.1007/s10549-018-4716.
    PubMed     Text format     Abstract available


  415. DEHDASHTI F, Wu N, Bose R, Naughton MJ, et al
    Evaluation of [(89)Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4696.
    PubMed     Text format     Abstract available


  416. COLLARINO A, Valdes Olmos RA, van Berkel LGAJ, Neijenhuis PA, et al
    The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery.
    Breast Cancer Res Treat. 2018 Feb 13. pii: 10.1007/s10549-018-4706.
    PubMed     Text format     Abstract available


  417. CHANG JH, Shin KH, Ahn SD, Park HJ, et al
    Chest wall recurrence in pT1-2N0-1 breast cancer patients after mastectomy without radiotherapy.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4707.
    PubMed     Text format     Abstract available


  418. HOLLINGSWORTH AB
    Is invasion a necessary step for metastases in breast cancer? Narod SA, Sopik V.
    Breast Cancer Res Treat. 2018 Feb 12. pii: 10.1007/s10549-018-4702.
    PubMed     Text format    


  419. XIE B, Yuan Z, Yang Y, Sun Z, et al
    MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4708.
    PubMed     Text format     Abstract available


  420. SKAANE P, Sebuodegard S, Bandos AI, Gur D, et al
    Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4705.
    PubMed     Text format     Abstract available


  421. DE MULDER H, Laenen A, Wildiers H, Punie K, et al
    Breast cancer subtype and survival by parity and time since last birth.
    Breast Cancer Res Treat. 2018 Feb 10. pii: 10.1007/s10549-018-4701.
    PubMed     Text format     Abstract available


  422. MIYAKE KK, Nakamoto Y, Saji S, Sugie T, et al
    Impact of physiological hormonal fluctuations on (18)F-fluorodeoxyglucose uptake in breast cancer.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4711.
    PubMed     Text format     Abstract available


  423. GOLDVASER H, Majeed H, Ribnikar D, Seruga B, et al
    Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis.
    Breast Cancer Res Treat. 2018 Feb 8. pii: 10.1007/s10549-018-4710.
    PubMed     Text format     Abstract available


  424. COSTA RLB, Han HS, Gradishar WJ
    Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Breast Cancer Res Treat. 2018 Feb 7. pii: 10.1007/s10549-018-4697.
    PubMed     Text format     Abstract available


  425. ZAREI N, Fazeli M, Mohammadi M, Nejatollahi F, et al
    Cell growth inhibition and apoptosis in breast cancer cells induced by anti-FZD7 scFvs: involvement of bioinformatics-based design of novel epitopes.
    Breast Cancer Res Treat. 2018 Feb 6. pii: 10.1007/s10549-017-4641.
    PubMed     Text format     Abstract available


  426. LAMMERT J, Lubinski J, Gronwald J, Huzarski T, et al
    Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-018-4694.
    PubMed     Text format     Abstract available


  427. JANNI W, Alba E, Bachelot T, Diab S, et al
    First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
    Breast Cancer Res Treat. 2018 Feb 5. pii: 10.1007/s10549-017-4658.
    PubMed     Text format     Abstract available


  428. VALDORA F, Houssami N, Rossi F, Calabrese M, et al
    Rapid review: radiomics and breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-018-4675.
    PubMed     Text format     Abstract available


  429. FOLDI J, Mougalian S, Silber A, Lannin D, et al
    Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
    Breast Cancer Res Treat. 2018 Feb 2. pii: 10.1007/s10549-017-4653.
    PubMed     Text format     Abstract available


  430. ZHOU S, Wang L, Yang Q, Liu H, et al
    Systematical analysis of lncRNA-mRNA competing endogenous RNA network in breast cancer subtypes.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4678.
    PubMed     Text format     Abstract available


  431. MATOSSIAN MD, Burks HE, Bowles AC, Elliott S, et al
    A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
    Breast Cancer Res Treat. 2018 Feb 1. pii: 10.1007/s10549-018-4685.
    PubMed     Text format     Abstract available


    January 2018
  432. LEE SB, Sohn G, Kim J, Chung IY, et al
    A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
    Breast Cancer Res Treat. 2018 Jan 31. pii: 10.1007/s10549-018-4682.
    PubMed     Text format     Abstract available


  433. HWANG KT, Kim EK, Jung SH, Lee ES, et al
    Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database.
    Breast Cancer Res Treat. 2018 Jan 30. pii: 10.1007/s10549-018-4681.
    PubMed     Text format     Abstract available


  434. JANSSON S, Aaltonen K, Bendahl PO, Falck AK, et al
    The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence.
    Breast Cancer Res Treat. 2018 Jan 29. pii: 10.1007/s10549-018-4664.
    PubMed     Text format     Abstract available


  435. FAIRWEATHER M, Jiang W, Keating NL, Freedman RA, et al
    Morbidity of local therapy for locally advanced metastatic breast cancer: an analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare Registry.
    Breast Cancer Res Treat. 2018 Jan 27. pii: 10.1007/s10549-018-4689.
    PubMed     Text format     Abstract available


  436. ZHANG L, Yu Q, Wu XC, Hsieh MC, et al
    Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-017-4646.
    PubMed     Text format     Abstract available


  437. GOYAL NG, Levine BJ, Van Zee KJ, Naftalis E, et al
    Trajectories of quality of life following breast cancer diagnosis.
    Breast Cancer Res Treat. 2018 Jan 24. pii: 10.1007/s10549-018-4677.
    PubMed     Text format     Abstract available


  438. POURCELOT C, Orillard E, Nallet G, Dirand C, et al
    Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence.
    Breast Cancer Res Treat. 2018 Jan 23. pii: 10.1007/s10549-018-4676.
    PubMed     Text format     Abstract available


  439. FAN Z, Ouyang T, Li J, Wang T, et al
    Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Breast Cancer Res Treat. 2018 Jan 22. pii: 10.1007/s10549-018-4673.
    PubMed     Text format     Abstract available


  440. JONES T, Duquette D, Underhill M, Ming C, et al
    Surveillance for cancer recurrence in long-term young breast cancer survivors randomly selected from a statewide cancer registry.
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-018-4674.
    PubMed     Text format     Abstract available


  441. NAROD SA, Sopik V
    Is invasion a necessary step for metastases in breast cancer?
    Breast Cancer Res Treat. 2018 Jan 20. pii: 10.1007/s10549-017-4644.
    PubMed     Text format     Abstract available


  442. BAO T, Seidman A, Li Q, Seluzicki C, et al
    Living with chronic pain: perceptions of breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4670.
    PubMed     Text format     Abstract available


  443. ABRAHAM J, Caldera H, Coleman R, Elias A, et al
    Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).
    Breast Cancer Res Treat. 2018 Jan 19. pii: 10.1007/s10549-018-4662.
    PubMed     Text format     Abstract available


  444. MIJWEL S, Backman M, Bolam KA, Olofsson E, et al
    Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4663.
    PubMed     Text format     Abstract available


  445. PEDERSON HJ, Hussain N, Noss R, Yanda C, et al
    Impact of an embedded genetic counselor on breast cancer treatment.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-017-4643.
    PubMed     Text format     Abstract available


  446. KOOPMAN T, Buikema HJ, Hollema H, de Bock GH, et al
    Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Breast Cancer Res Treat. 2018 Jan 18. pii: 10.1007/s10549-018-4669.
    PubMed     Text format     Abstract available


  447. BREYER JZ, Wendland EM, Kops NL, Caleffi M, et al
    Assessment of potential risk factors for breast cancer in a population in Southern Brazil.
    Breast Cancer Res Treat. 2018 Jan 17. pii: 10.1007/s10549-017-4655.
    PubMed     Text format     Abstract available


  448. GARCIA GARRE E, Luengo Gil G, Montoro Garcia S, Gonzalez Billalabeitia E, et al
    Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4656.
    PubMed     Text format     Abstract available


  449. CHENG J, Holland-Letz T, Wallwiener M, Surowy H, et al
    Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-018-4666.
    PubMed     Text format     Abstract available


  450. NI YB, Tsang JYS, Shao MM, Chan SK, et al
    GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 16. pii: 10.1007/s10549-017-4645.
    PubMed     Text format     Abstract available


  451. FOSTIRA F, Saloustros E, Apostolou P, Vagena A, et al
    Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-018-4661.
    PubMed     Text format     Abstract available


  452. JAKIMOVSKA M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, et al
    BRCA1 and BRCA2 germline variants in breast cancer patients from the Republic of Macedonia.
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4642.
    PubMed     Text format     Abstract available


  453. LAMBERTINI M, Fontanella C
    How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 15. pii: 10.1007/s10549-017-4654.
    PubMed     Text format    


  454. POORVU PD, Vaz-Luis I, Freedman RA, Lin NU, et al
    Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4659.
    PubMed     Text format     Abstract available


  455. ZHANG Y, Ji Y, Li J, Lei L, et al
    Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-018-4660.
    PubMed     Text format     Abstract available


  456. PAN K, Hurria A, Chlebowski RT
    Breast cancer survivorship: state of the science.
    Breast Cancer Res Treat. 2018 Jan 13. pii: 10.1007/s10549-017-4650.
    PubMed     Text format     Abstract available


  457. PAN Y, Heisig SR, von Blanckenburg P, Albert US, et al
    Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4637.
    PubMed     Text format     Abstract available


  458. NUNCIA-CANTARERO M, Martinez-Canales S, Andres-Pretel F, Santpere G, et al
    Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4652.
    PubMed     Text format     Abstract available


  459. TAN Q, Wei C
    Comment on a meta-analysis evaluating the cardiac toxicity of lapatinib in patients with breast cancer and other HER2-positive cancers.
    Breast Cancer Res Treat. 2018 Jan 12. pii: 10.1007/s10549-017-4648.
    PubMed     Text format    


  460. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Correction to: Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2018 Jan 11. pii: 10.1007/s10549-017-4634.
    PubMed     Text format     Abstract available



  461. 1st UK Interdisciplinary Breast Cancer Symposium-15th-16th January 2018.
    Breast Cancer Res Treat. 2018 Jan 10. pii: 10.1007/s10549-017-4585.
    PubMed     Text format    


  462. LILJEGREN A, von Wachenfeldt A, Azavedo E, Eloranta S, et al
    Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    Breast Cancer Res Treat. 2018 Jan 9. pii: 10.1007/s10549-017-4639.
    PubMed     Text format     Abstract available


  463. CHAE JW, Chua PS, Ng T, Yeo AHL, et al
    Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study.
    Breast Cancer Res Treat. 2018 Jan 8. pii: 10.1007/s10549-017-4640.
    PubMed     Text format     Abstract available


  464. BRAVACCINI S, Rocca A, Bronte G
    Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer?
    Breast Cancer Res Treat. 2018 Jan 6. pii: 10.1007/s10549-017-4630.
    PubMed     Text format    


  465. ASADUZZAMAN M, Constantinou S, Min H, Gallon J, et al
    Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Breast Cancer Res Treat. 2018 Jan 5. pii: 10.1007/s10549-017-4633.
    PubMed     Text format     Abstract available


  466. WANG S, Qian F, Zheng Y, Ogundiran T, et al
    Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry.
    Breast Cancer Res Treat. 2018 Jan 4. pii: 10.1007/s10549-017-4638.
    PubMed     Text format     Abstract available


  467. KOSTEV K, Kalder M
    20-year risk of breast cancer recurrence.
    Breast Cancer Res Treat. 2018 Jan 3. pii: 10.1007/s10549-017-4636.
    PubMed     Text format    


    December 2017
  468. HADDAD TC, D'Assoro A, Suman V, Opyrchal M, et al
    Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 30. pii: 10.1007/s10549-017-4616.
    PubMed     Text format     Abstract available


  469. PONDE N, Bradbury I, Lambertini M, Ewer M, et al
    Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).
    Breast Cancer Res Treat. 2017 Dec 27. pii: 10.1007/s10549-017-4628.
    PubMed     Text format     Abstract available


  470. KOSTEV K, Kalder M
    Long-term use of basal insulin and the risk of breast cancer.
    Breast Cancer Res Treat. 2017 Dec 26. pii: 10.1007/s10549-017-4631.
    PubMed     Text format    


  471. TELLI ML, Hellyer J, Audeh W, Jensen KC, et al
    Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    Breast Cancer Res Treat. 2017 Dec 23. pii: 10.1007/s10549-017-4624.
    PubMed     Text format     Abstract available


  472. FAZZINO TL, Klemp J, Befort C
    Late breast cancer treatment-related symptoms and functioning: associations with physical activity adoption and maintenance during a lifestyle intervention for rural survivors.
    Breast Cancer Res Treat. 2017 Dec 22. pii: 10.1007/s10549-017-4603.
    PubMed     Text format     Abstract available


  473. PICHILINGUE-FEBRES AF, Arias-Linares MA, Araujo-Castillo RV
    Comments on "Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors" by Parise CA and Caggiano V, Breast Cancer Res Treat, 2017.
    Breast Cancer Res Treat. 2017 Dec 21. pii: 10.1007/s10549-017-4620.
    PubMed     Text format     Abstract available


  474. UNDERWOOD EA, Rochon PA, Moineddin R, Lee PE, et al
    Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.
    Breast Cancer Res Treat. 2017 Dec 20. pii: 10.1007/s10549-017-4627.
    PubMed     Text format     Abstract available


  475. DUGGAN C, Baumgartner RN, Baumgartner KB, Bernstein L, et al
    Genetic variation in TNFalpha, PPARgamma, and IRS-1 genes, and their association with breast-cancer survival in the HEAL cohort.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4621.
    PubMed     Text format     Abstract available


  476. VAN SEIJEN M, Mooyaart AL, Mulder L, Hoogstraat M, et al
    Enrichment of high-grade tumors in breast cancer gene expression studies.
    Breast Cancer Res Treat. 2017 Dec 18. pii: 10.1007/s10549-017-4622.
    PubMed     Text format     Abstract available


  477. KWAN ML, Yao S, Laurent CA, Roh JM, et al
    Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Breast Cancer Res Treat. 2017 Dec 16. pii: 10.1007/s10549-017-4626.
    PubMed     Text format     Abstract available


  478. DU RUSQUEC P, Palpacuer C, Campion L, Patsouris A, et al
    Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4623.
    PubMed     Text format     Abstract available


  479. NAROD SA, Huzarski T, Gronwald J, Byrski T, et al
    Predictors of survival for breast cancer patients with a BRCA1 mutation.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4605.
    PubMed     Text format     Abstract available


  480. ZIMMER AS, Zhu K, Steeg PS, Wu A, et al
    Analysis of breast cancer in young women in the Department of Defense (DOD) database.
    Breast Cancer Res Treat. 2017 Dec 15. pii: 10.1007/s10549-017-4615.
    PubMed     Text format     Abstract available


  481. FALANDRY C, Krakowski I, Cure H, Carola E, et al
    Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.
    Breast Cancer Res Treat. 2017 Dec 14. pii: 10.1007/s10549-017-4607.
    PubMed     Text format     Abstract available


  482. FANG H, Huang D, Yang F, Guan X, et al
    Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Dec 13. pii: 10.1007/s10549-017-4612.
    PubMed     Text format     Abstract available


  483. HAN SN, Amant F, Cardonick EH, Loibl S, et al
    Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4611.
    PubMed     Text format     Abstract available


  484. BENS A, Papadopoulos FC, Pukkala E, Ekbom A, et al
    Worse survival after breast cancer in women with anorexia nervosa.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4618.
    PubMed     Text format     Abstract available


  485. VAN VULPEN JK, Schmidt ME, Velthuis MJ, Wiskemann J, et al
    Effects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4608.
    PubMed     Text format     Abstract available


  486. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
    Breast Cancer Res Treat. 2017 Dec 12. pii: 10.1007/s10549-017-4601.
    PubMed     Text format     Abstract available


  487. SPEIGL L, Burow H, Bailur JK, Janssen N, et al
    CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4594.
    PubMed     Text format     Abstract available


  488. XIE J, Cao J, Wang JF, Zhang BH, et al
    Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4609.
    PubMed     Text format     Abstract available


  489. SINGH K, He X, Kalife ET, Ehdaivand S, et al
    Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4619.
    PubMed     Text format     Abstract available


  490. LI W, Kwok CC, Chan DC, Wang F, et al
    Weak circadian rhythm increases neutropenia risk among breast cancer patients undergoing adjuvant chemotherapy.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4614.
    PubMed     Text format     Abstract available


  491. NOMURA SJO, Hwang YT, Gomez SL, Fung TT, et al
    Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.
    Breast Cancer Res Treat. 2017 Dec 11. pii: 10.1007/s10549-017-4578.
    PubMed     Text format     Abstract available


  492. IBRAHIM MFK, Hilton J, Mazzarello S, Fergusson D, et al
    A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4604.
    PubMed     Text format     Abstract available


  493. WANG J, Fan T, He Y, Chen X, et al
    (99m)Tc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis.
    Breast Cancer Res Treat. 2017 Dec 6. pii: 10.1007/s10549-017-4591.
    PubMed     Text format     Abstract available


  494. PISTILLI B, Pluard T, Urruticoechea A, Farci D, et al
    Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Breast Cancer Res Treat. 2017 Dec 2. pii: 10.1007/s10549-017-4596.
    PubMed     Text format     Abstract available


    November 2017
  495. REINERT T, Debiasi M, Bines J, Barrios CH, et al
    Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4593.
    PubMed     Text format     Abstract available


  496. XIA Z, Baumgartner KB, Baumgartner RN, Boone SD, et al
    Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4600.
    PubMed     Text format     Abstract available


  497. MATIKAS A, Margolin S, Hellstrom M, Johansson H, et al
    Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 30. pii: 10.1007/s10549-017-4599.
    PubMed     Text format     Abstract available


  498. YU YF, Wang Y, Fu TP, Chen K, et al
    Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 29. pii: 10.1007/s10549-017-4592.
    PubMed     Text format     Abstract available


  499. WANG Z, Kong J, Wu Y, Zhang J, et al
    PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4597.
    PubMed     Text format     Abstract available


  500. TRENTHAM-DIETZ A, Ergun MA, Alagoz O, Stout NK, et al
    Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
    Breast Cancer Res Treat. 2017 Nov 28. pii: 10.1007/s10549-017-4582.
    PubMed     Text format     Abstract available


  501. LOHRISCH C, Francl M, Sun S, Villa D, et al
    Willingness of breast cancer patients to undergo biopsy and breast cancer clinicians' practices around seeking biopsy at the time of breast cancer relapse.
    Breast Cancer Res Treat. 2017 Nov 27. pii: 10.1007/s10549-017-4586.
    PubMed     Text format     Abstract available


  502. VILLEGAS SL, Darb-Esfahani S, von Minckwitz G, Huober J, et al
    Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Breast Cancer Res Treat. 2017 Nov 25. pii: 10.1007/s10549-017-4581.
    PubMed     Text format     Abstract available


  503. LIU YL, Connolly EP, Kalinsky K
    Obesity's impact on survival is independent of dose adjustments in neoadjuvant chemotherapy in women with breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4590.
    PubMed     Text format    


  504. PEZO RC, Chen TW, Berman HK, Mulligan AM, et al
    Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4580.
    PubMed     Text format     Abstract available


  505. ALTUNDAG K
    Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?
    Breast Cancer Res Treat. 2017 Nov 24. pii: 10.1007/s10549-017-4589.
    PubMed     Text format    


  506. COLOMER R, Hall P, Szkultecka-Debek M, Bondi RC, et al
    Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
    Breast Cancer Res Treat. 2017 Nov 23. pii: 10.1007/s10549-017-4567.
    PubMed     Text format     Abstract available


  507. LECLERC M, Neuhausen SL, Schayek H, Laitman Y, et al
    Are VNTRs co-localizing with breast cancer-associated SNPs?
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4588.
    PubMed     Text format     Abstract available


  508. DIELI-CONWRIGHT CM, Parmentier JH, Sami N, Lee K, et al
    Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention.
    Breast Cancer Res Treat. 2017 Nov 22. doi: 10.1007/s10549-017-4576.
    PubMed     Text format     Abstract available


  509. O'SHAUGHNESSY J, Petrakova K, Sonke GS, Conte P, et al
    Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4518.
    PubMed     Text format     Abstract available


  510. NILSSON MP, Torngren T, Henriksson K, Kristoffersson U, et al
    BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    Breast Cancer Res Treat. 2017 Nov 21. doi: 10.1007/s10549-017-4584.
    PubMed     Text format     Abstract available


  511. ASLEH K, Won JR, Gao D, Voduc KD, et al
    Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4583.
    PubMed     Text format     Abstract available


  512. BROUCKAERT O, Van Asten K, Laenen A, Soubry A, et al
    Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
    Breast Cancer Res Treat. 2017 Nov 20. doi: 10.1007/s10549-017-4579.
    PubMed     Text format     Abstract available


  513. RIER HN, Jager A, Sleijfer S, van Rosmalen J, et al
    Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Nov 17. doi: 10.1007/s10549-017-4574.
    PubMed     Text format     Abstract available


  514. ABDEL-RAHMAN O
    Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.
    Breast Cancer Res Treat. 2017 Nov 15. doi: 10.1007/s10549-017-4577.
    PubMed     Text format     Abstract available


  515. MIJWEL S, Backman M, Bolam KA, Jervaeus A, et al
    Adding high-intensity interval training to conventional training modalities: optimizing health-related outcomes during chemotherapy for breast cancer: the OptiTrain randomized controlled trial.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4571.
    PubMed     Text format     Abstract available


  516. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Correction to: Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Nov 14. doi: 10.1007/s10549-017-4568.
    PubMed     Text format     Abstract available


  517. MENESES K, Benz R, Bail JR, Vo JB, et al
    Speed of processing training in middle-aged and older breast cancer survivors (SOAR): results of a randomized controlled pilot.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4564.
    PubMed     Text format     Abstract available


  518. DODSON A, Okonji D, Assersohn L, Rigg A, et al
    Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4514.
    PubMed     Text format     Abstract available


  519. BOSTNER J, Alayev A, Berman AY, Fornander T, et al
    Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 11. doi: 10.1007/s10549-017-4508.
    PubMed     Text format     Abstract available


  520. GILLMAN AS, Gardiner CK, Koljack CE, Bryan AD, et al
    Body mass index, diet, and exercise: testing possible linkages to breast cancer risk via DNA methylation.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4573.
    PubMed     Text format     Abstract available


  521. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Correction to: Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Nov 10. doi: 10.1007/s10549-017-4569.
    PubMed     Text format     Abstract available


  522. KWA M, Li X, Novik Y, Oratz R, et al
    Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4570.
    PubMed     Text format     Abstract available


  523. NYROP KA, Deal AM, Choi SK, Wagoner CW, et al
    Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer.
    Breast Cancer Res Treat. 2017 Nov 9. doi: 10.1007/s10549-017-4565.
    PubMed     Text format     Abstract available


  524. LYNCE F, Blackburn MJ, Cai L, Wang H, et al
    Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4563.
    PubMed     Text format     Abstract available


  525. SOPIK V, Sun P, Narod SA
    Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2017 Nov 8. doi: 10.1007/s10549-017-4572.
    PubMed     Text format     Abstract available


  526. BRIANESE RC, Nakamura KDM, Almeida FGDSR, Ramalho RF, et al
    BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4552.
    PubMed     Text format     Abstract available


  527. EVANS DG, Harkness EF, Howel S, Woodward ER, et al
    Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4557.
    PubMed     Text format     Abstract available


  528. GOING CC, Alexandrova L, Lau K, Yeh CY, et al
    Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4562.
    PubMed     Text format     Abstract available


  529. MURPHY BL, Zalewski NL, Degnim AC, McKeon A, et al
    Breast cancer-related paraneoplastic neurologic disease.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4566.
    PubMed     Text format     Abstract available


  530. RIMAWI MF, De Angelis C, Contreras A, Pareja F, et al
    Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Breast Cancer Res Treat. 2017 Nov 7. doi: 10.1007/s10549-017-4533.
    PubMed     Text format     Abstract available


  531. LAMBERT LK, Balneaves LG, Howard AF, Gotay CC, et al
    Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4561.
    PubMed     Text format     Abstract available


  532. KIRKHAM AA, Eves ND, Shave RE, Bland KA, et al
    The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.
    Breast Cancer Res Treat. 2017 Nov 6. doi: 10.1007/s10549-017-4554.
    PubMed     Text format     Abstract available


  533. FREEDMAN RA, Tolaney SM
    Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Breast Cancer Res Treat. 2017 Nov 4. doi: 10.1007/s10549-017-4560.
    PubMed     Text format     Abstract available


  534. RODRIGUEZ-WALLBERG KA, Eloranta S, Krawiec K, Lissmats A, et al
    Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
    Breast Cancer Res Treat. 2017 Nov 2. doi: 10.1007/s10549-017-4555.
    PubMed     Text format     Abstract available


    October 2017
  535. NGUYEN F, Pena L, Ibisch C, Loussouarn D, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4548.
    PubMed     Text format     Abstract available


  536. RABOW M, Small R, Jow A, Majure M, et al
    The value of embedding: integrated palliative care for patients with metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Oct 30. doi: 10.1007/s10549-017-4556.
    PubMed     Text format     Abstract available


  537. PALMIERI C, Stein RC, Liu X, Hudson E, et al
    Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
    Breast Cancer Res Treat. 2017 Oct 25. doi: 10.1007/s10549-017-4539.
    PubMed     Text format     Abstract available


  538. BOCK CH, Jay AM, Dyson G, Beebe-Dimmer JL, et al
    The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.
    Breast Cancer Res Treat. 2017 Oct 24. doi: 10.1007/s10549-017-4521.
    PubMed     Text format     Abstract available


  539. DIRIX LY, Takacs I, Jerusalem G, Nikolinakos P, et al
    Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4537.
    PubMed     Text format     Abstract available


  540. ABADIE J, Nguyen F, Loussouarn D, Pena L, et al
    Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4542.
    PubMed     Text format     Abstract available


  541. ALTUNDAG K
    Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4544.
    PubMed     Text format    


  542. HAYES SC, Steele ML, Spence RR, Gordon L, et al
    Exercise following breast cancer: exploratory survival analyses of two randomised, controlled trials.
    Breast Cancer Res Treat. 2017 Oct 23. doi: 10.1007/s10549-017-4541.
    PubMed     Text format     Abstract available


  543. SONKE GS, Hart LL, Campone M, Erdkamp F, et al
    Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
    Breast Cancer Res Treat. 2017 Oct 22. doi: 10.1007/s10549-017-4523.
    PubMed     Text format     Abstract available


  544. TAN Q, Qin Q
    Does the elevation of CAMLs predict metastatic breast cancer patients' survival?
    Breast Cancer Res Treat. 2017 Oct 20. doi: 10.1007/s10549-017-4546.
    PubMed     Text format    


  545. MORDANG JJ, Gubern-Merida A, Bria A, Tortorella F, et al
    The importance of early detection of calcifications associated with breast cancer in screening.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4527.
    PubMed     Text format     Abstract available


  546. LUBINSKI J, Marciniak W, Muszynska M, Huzarski T, et al
    Serum selenium levels predict survival after breast cancer.
    Breast Cancer Res Treat. 2017 Oct 17. doi: 10.1007/s10549-017-4525.
    PubMed     Text format     Abstract available


  547. MALMGREN JA, Mayer M, Atwood MK, Kaplan HG, et al
    Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4529.
    PubMed     Text format     Abstract available


  548. SCHON K, Tischkowitz M
    Clinical implications of germline mutations in breast cancer: TP53.
    Breast Cancer Res Treat. 2017 Oct 16. doi: 10.1007/s10549-017-4531.
    PubMed     Text format     Abstract available


  549. FIETZ T, Zahn MO, Kohler A, Engel E, et al
    Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4534.
    PubMed     Text format     Abstract available


  550. CHOI BH, Choi N, Kim MY, Yang JH, et al
    Usefulness of abbreviated breast MRI screening for women with a history of breast cancer surgery.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4530.
    PubMed     Text format     Abstract available


  551. BERNSTEIN V, Ellard SL, Dent SF, Tu D, et al
    A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
    Breast Cancer Res Treat. 2017 Oct 13. doi: 10.1007/s10549-017-4538.
    PubMed     Text format     Abstract available


  552. ADACHI Y, Yoshimura M, Nishida K, Usuki H, et al
    Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models.
    Breast Cancer Res Treat. 2017 Oct 12. doi: 10.1007/s10549-017-4532.
    PubMed     Text format     Abstract available


  553. ALTUNDAG K
    Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
    Breast Cancer Res Treat. 2017 Oct 11. doi: 10.1007/s10549-017-4536.
    PubMed     Text format    


  554. DOMINICI LS, Sineshaw HM, Jemal A, Lin CC, et al
    Patterns of axillary evaluation in older patients with breast cancer and associations with adjuvant therapy receipt.
    Breast Cancer Res Treat. 2017 Oct 9. doi: 10.1007/s10549-017-4528.
    PubMed     Text format     Abstract available


  555. PAGE DB, Wen H, Brogi E, Dure D, et al
    Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
    Breast Cancer Res Treat. 2017 Oct 6. doi: 10.1007/s10549-017-4520.
    PubMed     Text format     Abstract available


  556. KAIDAR-PERSON O, Meattini I, Jain P, Bult P, et al
    Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study.
    Breast Cancer Res Treat. 2017 Oct 3. doi: 10.1007/s10549-017-4526.
    PubMed     Text format     Abstract available


    September 2017
  557. XIA J, Tang Z, Deng Q, Yang R, et al
    Predictors of the quality of life in Chinese breast cancer survivors.
    Breast Cancer Res Treat. 2017 Sep 30. doi: 10.1007/s10549-017-4512.
    PubMed     Text format     Abstract available


  558. GALLARDO A, Lerma E
    Response letter to: Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4524.
    PubMed     Text format    


  559. ALTUNDAG K
    Questions about Ki67 staining in luminal breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4515.
    PubMed     Text format    


  560. LUU T, Kim KP, Blanchard S, Anyang B, et al
    Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4516.
    PubMed     Text format     Abstract available


  561. TSOUTSOU PG, Durham AD, Vozenin MC
    A need for biology-driven personalized radiotherapy in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 27. doi: 10.1007/s10549-017-4522.
    PubMed     Text format    


  562. SAYED S, Moloo Z, Wasike R, Bird P, et al
    Ethnicity and breast cancer characteristics in Kenya.
    Breast Cancer Res Treat. 2017 Sep 26. doi: 10.1007/s10549-017-4511.
    PubMed     Text format     Abstract available


  563. LIU YL, Saraf A, Catanese B, Lee SM, et al
    Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4507.
    PubMed     Text format     Abstract available


  564. CRONIN-FENTON D, Kjaersgaard A, Norgaard M, Amelio J, et al
    Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.
    Breast Cancer Res Treat. 2017 Sep 25. doi: 10.1007/s10549-017-4510.
    PubMed     Text format     Abstract available


  565. KAUFMAN DI, Shah C, Vicini FA, Rizzi M, et al
    Erratum to: Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.
    Breast Cancer Res Treat. 2017 Sep 20. doi: 10.1007/s10549-017-4505.
    PubMed     Text format     Abstract available


  566. RICE BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, et al
    Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat. 2017 Sep 18. doi: 10.1007/s10549-017-4506.
    PubMed     Text format     Abstract available


  567. JEONG IJ, Lee SG, Kim YH, Ko BS, et al
    Characteristics and prognosis of breast cancer after liver or kidney transplantation.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4504.
    PubMed     Text format     Abstract available


  568. GIANNAKEAS V, Narod SA
    The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    Breast Cancer Res Treat. 2017 Sep 15. doi: 10.1007/s10549-017-4476.
    PubMed     Text format     Abstract available


  569. LEON-FERRE RA, Polley MY, Liu H, Gilbert JA, et al
    Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4499.
    PubMed     Text format     Abstract available


  570. NYROP KA, Deal AM, Lee JT, Muss HB, et al
    Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4501.
    PubMed     Text format     Abstract available


  571. SIEGELMANN-DANIELI N, Katzir I, Landes JV, Segal Y, et al
    Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.
    Breast Cancer Res Treat. 2017 Sep 14. doi: 10.1007/s10549-017-4491.
    PubMed     Text format     Abstract available


  572. KOCHI M, Iwamoto T, Niikura N, Bianchini G, et al
    Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4502.
    PubMed     Text format     Abstract available


  573. MASUNAGA N, Kagara N, Motooka D, Nakamura S, et al
    Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
    Breast Cancer Res Treat. 2017 Sep 13. doi: 10.1007/s10549-017-4487.
    PubMed     Text format     Abstract available


  574. ROCQUE GB, Williams CP, Jones MI, Kenzik KM, et al
    Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.
    Breast Cancer Res Treat. 2017 Sep 12. doi: 10.1007/s10549-017-4498.
    PubMed     Text format     Abstract available


  575. NIIKURA N, Shimomura A, Fukatsu Y, Sawaki M, et al
    Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4489.
    PubMed     Text format     Abstract available


  576. GREGOROWITSCH ML, van den Bongard HJGD, Young-Afat DA, Pignol JP, et al
    Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients.
    Breast Cancer Res Treat. 2017 Sep 11. doi: 10.1007/s10549-017-4495.
    PubMed     Text format     Abstract available


  577. SAUNUS JM, Smart CE, Kutasovic JR, Johnston RL, et al
    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res Treat. 2017 Sep 9. doi: 10.1007/s10549-017-4496.
    PubMed     Text format     Abstract available


    August 2017
  578. WEBER WP, Soysal SD, El-Tamer M, Sacchini V, et al
    First international consensus conference on standardization of oncoplastic breast conserving surgery.
    Breast Cancer Res Treat. 2017;165:139-149.
    PubMed     Text format     Abstract available


  579. CONT NT, Maggiorotto F, Martincich L, Rivolin A, et al
    Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy.
    Breast Cancer Res Treat. 2017;165:85-95.
    PubMed     Text format     Abstract available


    June 2017
  580. SANTEN RJ, Radisky DC, Degnim A, Frost MH, et al
    Aromatase expression in atypical ductal hyperplasia in women.
    Breast Cancer Res Treat. 2017;163:623-629.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: